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 Robert Ferrell, PhD 
 
C-peptide, historically considered a biologically inactive peptide, has been shown to exert insulin-
independent biological effects on a number of cells proving itself as a bioactive peptide with anti-
inflammatory properties.  Type 1 diabetes (T1D) patients typically lack physiological levels of 
insulin and C-peptide and are at increased risk of developing complications affecting the vessels of 
the eye, the kidneys, and the peripheral nerves. Inflammation is an important factor for the 
development of diabetes-associated vascular complications, and there is increasing evidence that 
T1D patients, even at a young age and after short duration of T1D, have circulating activated 
monocytes and increased plasma levels of inflammatory cytokines.  
It has been hypothesized that lack of circulating C-peptide might contribute to the 
development of diabetes-associated vascular complications by reducing the inflammatory response 
associated with T1D. In this study, we investigated the direct effect of C-peptide on several 
inflammatory processes of vascular damage, such as endothelial dysfunction and monocyte 
activation.  
In an hyperglycaemia-induced model of vascular dysfunction, we found that C-peptide 
exerted its beneficial effect on a variety of inflammatory events such as cytokines secretions, 
adhesion molecules expression, oxidative stress generation, and cellular proliferation. Finally, to 
gain insights on the cell biology of C-peptide, we investigated its process of from the cell surface 
and its sub-cellular localization in target cells. Our findings indicate that C-peptide internalization 
from the cell surface within membrane-bound organelles of the endocytic pathway and excluded 
direct translocation across the plasma membrane. The importance of this finding is that endosomes 
represent intracellular sites from which C-peptide affects key signaling pathways in target cell.  
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The present evidences favor the view that replacement therapy with C-peptide in T1D 
patients has a critical public health impact for decreasing diabetic complications. In fact C-peptide 
therapy replacement offers an approach to retard the development of diabetes-associated vascular 
complications, for which no causal therapy is available today.  
Much of the burden of diabetes is due to the development of microvascular complications 
including retinopathy, nephropathy and neuropathy. The prevention and treatment of 
microvascular complications are of critical importance to decrease the associated mortality and 
morbidity.  
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EEA1                           Early endosome antigen 1 
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1.0  INTRODUCTION 
Human C-peptide is a 31 amino acid long peptide secreted by pancreatic #-cells. In 
healthy individuals, C-peptide is secreted in the peripheral circulation in equimolar amount with 
insulin in response to elevated blood glucose levels (hyperglycemia), but it is absent in the 
majority of T1D patients 1-3. C-peptide was considered biologically inactive and necessary only 
for proinsulin folding within beta-cells4-5. Research during the last years has provided direct and 
robust evidence that C-peptide is in effect capable of insulin-independent biological effects in 
many different cell types (Figure 1), where it affects activation of several intracellular pathways, 
such as, but not limited to, those involved in cellular proliferation and inflammation 6-8.  
Patients with T1D exhibit an increased susceptibility to develop a wide range of vascular 
complications, including microangiopathy and atherosclerosis, which account for the majority of 
deaths and disability in diabetic patients9-11. To date, no treatment has been implemented in order 
to delay or prevent the development of vascular complications. It has been proposed that C-
peptide exerts beneficial effects on the vasculature, especially when the vasculature is exposed to 
insults such as during T1D. Importantly, results from small clinical trials have demonstrated that 
C-peptide is beneficial when administered as replacement therapy to T1D patients who suffers 
from diabetic vascular complications, in particular in relation to nephropathy, neuropathy, and 
augmentation of blood flow12-15. Vascular disease in diabetes originates at the level of the 
endothelium with abnormalities in cellular function, a condition known as endothelial 
dysfunction that precedes the development of structural abnormalities and damage16. The healthy 
endothelium plays an important role in maintaining vessel wall homeostasis, synthesizing 
biologically active substances that modulate vascular tone and reactivity, preventing thrombosis, 
and influencing smooth muscle growth. In T1D some or all of these functions are altered.  
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Studies during the last decades have started unraveling the molecular mechanisms 
underlying the vascular effects of C-peptide. Several findings have shown that C-peptide affects 
leukocyte-endothelium interactions by reducing up-regulation of endothelial cell adhesion 
molecules typically observed under inflammatory conditions.  
 
 
 
Figure 1. C-peptide cellular targets documented in literature. 
 
 
The first evidence of this effect is from Scalia et al.17, who demonstrated that rats 
pretreated with C-peptide and injected with the inflammatory agents thrombin or NG-nitro-L-L-
arginine methyl ester (L-NAME), an agent causing acute endothelial dysfunction, resulted in 
reduced expression of ICAM-1 and P-selectin on the mesenteric microvascular endothelium. As 
a consequence, the number of rolling, adhering, and transmigrated leukocytes also decreased 
upon C-peptide administration to the animals. In another model of vascular injury, C-peptide 
decreased polymorphonuclear leukocyte (PMN) infiltration in isolated rat hearts following 
ischemia-reperfusion injury18. In this model, trans-endothelial migration of PMN to the sub-
endothelial layers represents a prominent step in the inflammatory component of post-ischemic 
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injury. PMN infiltration induces endothelial and myocardial injury by releasing cytotoxic 
substances such as oxygen-derived free radicals, inflammatory cytokines and proteolytic 
enzymes. In neutrophil-depleted animals undergoing reperfused myocardial infarction, the 
infarct size was significantly decreased demonstrating that a significant amount of myocardial 
injury is induced by neutrophil-associated mechanisms18,19. In the study by Young et al., 
systemic administration of C-peptide restored cardiac contractile function and postreperfusion 
coronary heart flow 18 by reducing PMN infiltration to the myocardium. 
Additionally, recent studies demonstrate the importance of C-peptide in modulating 
inflammatory pathways in the central nervous system. T1D patients may suffer impairments in 
learning, memory, problem solving, and mental and motor speed with primary diabetic 
encephalopathy recognized as a late complication of T1D20. In the type 1 BB/Wor rat (rat model 
of human T1D), cognitive impairment is associated with apoptosis-induced neuronal loss in the 
hippocampus, an event associated with transcription nuclear factor (NF)-!B and RAGE 
(Advanced Glycation End Products-Receptor) activation21. Elevated levels of the pro-
inflammatory cytokines TNF-", IL-1#, IL-2, and IL-6 were also present in these animals20. The 
up-regulation of RAGE and activation of NF-$B, TNF-", IL-1#, IL-2, and IL-6 were 
significantly reduced when the diabetic rats received C-peptide replacement which was also 
associated with the prevention of astrocyte proliferation8 and reduction of apoptosis20,22. 
However, the mechanisms able to produce the beneficial effects of C-peptide on vascular 
dysfunction during hyperglycaemia remain largely unknown.  
This study aimed to develop an in vitro experimental model to investigate the direct 
effect of C-peptide on several processes of vascular damage, such as endothelial dysfunction and 
monocyte activation. We therefore initiated a study on the direct effect of C-peptide testing 
Vascular Cell Adhesion Molecule-1 (VCAM-1) expression, monocyte adherence, and secretion 
of IL-8 and Monocyte Chemoactrant Protein(MCP)-1 by endothelial cells exposed to short-term 
high glucose. As part of the endothelial dysfunction, we also evaluated the effects of short-term 
exposure of C-peptide on high glucose-induced proliferation of human aortic and human 
umbilical smooth muscle cells in vitro.  
We then proceeded to study the process of human monocyte activation, a third 
component of the vascular damage. Specifically, we focused our investigation on the possible 
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anti-inflammatory effect(s) of C-peptide on cytokine release by Lypopolysaccharide (LPS)-
activated human monocytes. We obtained strong evidence that C-peptide exerts anti-
inflammatory properties on the endothelial and smooth muscle layers of vessel wall and 
circulating monocytes, neutralizing the deleterious effect inferred by hyperglycaemia. 
Since activation of the transcription factor NF-!B is involved in these pro-inflammatory 
responses, we also investigated the direct effect of C-peptide on nuclear translocation of the NF-
!B subunits p50/p65 in human endothelial cells, smooth muscle cells and monocyte. The study 
confirmed our hypothesis that physiologic concentrations of C-peptide protects the vasculature 
from high glucose-induced cellular dysfunction by decreasing NF-!B activation thus inhibiting 
NF-!B-dependent genes, such as VCAM-1, IL-8 and MCP-1 expression, and therefore affecting 
monocyte adhesion and smooth muscle cell proliferation.  
However, which NF-!B dependent upstream signaling event is affected by C-peptide in 
endothelial cells is not clear. Since reactive oxygen species (ROS) are powerful cellular 
activators of the NF-!B pathway in condition of hyperglycaemia23, we decided to investigate the 
effect of C-peptide on high glucose-induced ROS generation as the mechanism underlying its 
beneficial effects on endothelial cell dysfunction and apoptosis. We focused on the NAD(P)H 
oxidase pathway of ROS generation, which is the major pathway of ROS production in 
endothelial cells during diabetes.  
Finally, since very little is known about the cell biology of C-peptide, we investigated the 
process of internalization of C-peptide from the cell surface and sub-cellular localization of C-
peptide in target cells. Our findings indicate a process of C-peptide internalization from the cell 
surface within membrane-bound organelles of the endocytic pathway, and excluded direct 
translocation across the plasma membrane. 
In summary, we provide evidence of an anti-inflammatory effect of C-peptide on several 
cellular targets involved in vascular damage in diabetes. Based on the current findings, we 
support a model in which C-peptide actively enters endothelial cell (mechanism also shown in 
smooth muscle), co-localizes with early endosomes, and it is degraded in lysosomes. The effect 
of C-peptide on the NF-!B pathway might originate from a putative C-peptide/C-peptide-
receptor complex signaling from the either the plasma membrane or endosomes, as it has been 
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demonstrated for certain Toll-like receptor pathways and other inflammatory pathways, which 
affect activation of the NF-!B pathway from the endosomes 24,25. The mildly acidic pH of the 
sorting endosomes would then begin the dissociation of the C-peptide destined to lysosomes 
from its recycled receptor. C-peptide could inhibit the NF-!B pathway through an effect on the 
activity of NAD(P)H oxidase, the major ROS producer in endothelial cells, thus decreasing 
apoptosis and several markers of endothelial dysfunction. Future research will have to determine 
the specific contribution of these mechanism(s) in C-peptide anti-inflammatory signaling. 
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2.0  REVIEW OF RELEVANT LITERATURE 
2.1 What is C-peptide 
C-peptide or connecting peptide is the 31 amino acid segment that links the A and B chains of 
proinsulin and serves to promote the efficient folding, assembly and processing of the insulin 
molecule in the beta cell endoplasmic reticulum in the course of insulin biosynthesis (Figure 2)1. 
Equimolar amounts of insulin and C-peptide are subsequently stored in secretory granules of the 
beta cells and eventually released into the portal and systemic circulations. Unlike insulin, C-
peptide escapes hepatic retention and circulates at a concentration approximately 10-fold higher 
than that of insulin. The peptide is primarily catabolized by the kidneys and the biological half-
life of C-peptide is more than 30 min in adult humans, compared to 3-4 min for insulin2.  
Soon after its discovery in 1967 several investigators evaluated C-peptide for possible 
insulin-like effects but none were found. The apparent lack of physiological effects and 
consideration of the C-peptide structural variability and limited sequence conservation between 
species3 led to the general view that the peptide was devoid of physiological effects other than its 
role in insulin biosynthesis4. Instead, interest focused on the fact that it is co-secreted with 
insulin and that plasma concentrations of C-peptide effectively reflect the endogenous insulin 
secretion5. As a marker of insulin secretion, C-peptide has been of great value in furthering our 
understanding of the pathophysiology of both type 1 (T1D) and type 2 (T2D) diabetes. Even 
though C-peptide left the scientific limelight in the mid 1980s, interest in the possibility that the 
peptide may exert physiological effects remained. This notion was supported by the clinical 
observation of long standing that, compared to T1D patients in whom beta-cell function ceases 
totally, those patients who retain a low but detectable level of C-peptide are less prone to develop 
microvascular complications of the eyes, the kidneys and the peripheral nerves26, 27.  
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Figure 2. Proinsulin C-peptide molecule. In (a), is shown a tridimensional image of the proinsulin molecule, from 
which C-peptide is cleaved by endoproteases at the level of two Arginine residues linking the B-chain and C-peptide 
at the level of the Lysine-Arginine residues linking the C-peptide and the A-chain (in white). In Figure (b), is shown 
a schematic view of the proinsulin molecule. The black arrows indicate sites of cleavage by proteases at the level of 
Arginine residues. Once secreted into the bloodstream, C-peptide circulates at low nanomolar concentrations in 
healthy individuals, but it is absent in most patients with Type 1 Diabetes (T1D). 
 
This view has recently received support from a study involving a large cohort of T1D 
patients treated uniformly at one medical center. The results show that a C-peptide level above 
0.06 nM confers a statistically significant protective effect against the development of 
microvascular complications independently of glycemic control, duration of diabetes, age and 
sex28. Moreover, pancreas or islet transplantation, with restoration of endogenous insulin and C-
peptide secretion, are known to be accompanied by improvement of diabetes-induced 
abnormalities of nerve function, endothelial function and both structural and functional changes 
of the kidneys29, 30. 
 
 
 
 
a b 
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2.2  Type 1 Diabetes as multifactorial disorder 
T1D is a progressive autoimmune disease resulting from destruction of insulin-producing 
pancreatic beta cells31. The subsequent lack of insulin leads to a dramatic elevated blood glucose 
level (hyperglycemia) treated with exogenous long-life insulin treatment. The adjacent glucagon 
(alpha)- and somatostatin (delta)-producing cells in the pancreas are not affected. 
Hyperglycemia, glycosuria, polydipsia, and weight loss are some of the most significant early 
clinical signs and symptoms of the diabetic syndrome that arises when a major proportion of the 
beta-cells are destroyed. During the course of diabetes, most T1D patients gradually develop one 
or several histopathological lesions affecting the vasculature of both large and small blood 
vessels, leading to macro- and micro-vascular complications9. These lesions result in the 
development of accelerated atherosclerosis, coronary artery disease, visual impairment, renal 
dysfunction and sensory loss, all of which seriously affect the quality and life style of diabetic 
patients10,11,16,32. 
T1D is a multifactorial disease. Evidence so far indicates that the development of the 
disease is induced by a combination of genetic susceptibility, a diabetogenic trigger and exposure 
to a driving antigen 33,60. It is not known, however, whether all factors intervene concomitantly in 
a given individual or separately in a subset of patients or, whether a given environmental factor 
plays an etiological role in a selected genetic background31. A long list of environmental factors 
has been proposed and investigated mainly in case-control studies. Since increases in the 
occurrence of T1D are primarily seen in the youngest age groups in several countries, the focus 
of most investigators has been on exposures during the fetal, neonatal, and early childhood 
periods. The factors found to be associated with T1D include high birth weight, accelerated early 
growth, Coxsackie virus infection33 and other pathogen exposure during gestation and early 
childhood, dietary factors such breastfeeding, early exposure to cow’s milk, intake of essential 
nutrients, climatological factors such as environmental toxins and contaminants34,35. To date, 
none of these factors has been conclusively shown to influence the risk of T1D. 
 
2.2.1 Genetics 
Several lines of evidence indicate that the risk of developing T1D is at least partially determined 
by genetics. First, twin studies have revealed higher disease concordance rates among 
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monozygotic than dizygotic twins36. However, data from the same study suggests that T1D is 
affected by environmental factors since the concordance rate for T1D development between 
monozygotic twins is less than 50%.  
Genes for T1D provide both susceptibility towards, and protection from, the disease37. 
Although many chromosomal loci have been identified, few true genes have been associated 
with such activity. The genetics of T1D cannot be classified according to a specific model of 
dominant, recessive, or intermediate inheritance of a specific set of genes38.  
Studies, conducted in the early-70’, found that the Leukocyte Antigen (HLA) cluster 
region, on chromosome 6p21, is a critical susceptibility locus for T1D39,40. This region, 
commonly termed IDDM1 (insulin-dependent diabetes mellitus locus) is located within the 
major histocompatibility complex (MHC) region and accounts for about 45% of genetic 
susceptibility for the disease41. The function of these genes in terms of immune response is well 
known (e.g. presentation of antigenic peptides to T lymphocytes), yet their specific contributions 
to the pathogenesis of T1D remain still under investigation.  
After several decades of continuous progress since the discovery of HLA association, the 
class II genes remain the strongest genetic contributor42-44. T1D seems somewhat unique among 
autoimmune diseases in that in addition to forming susceptibility, certain MHC haplotypes 
provide significant protection, with protection dominant over susceptibility45 (Table 1). The 
importance of class II haplotype not only depends on the well-known risk for disease associated 
with HLA-DR3 and HLA-DR4, but also on additional susceptibility associated with DQ"-chains 
and DQ#-chains46.  
T1D represents a heterogeneous and polygenic disorder, with a number (about 20) of 
non-HLA loci contributing to the disease susceptibility already identified47. The IDDM2 region, 
on chromosome 11, maps to a variable number of tandem mini-satellite repeats (VNTR) in 
promoter region of insulin gene48,49. The magnitude of risk correlates with the number of those 
tandem repeats: VNTR type 1 (with shorter repeats) homozygous individuals are in higher risk 
category and VNTR type III (longer repeats) protects carriers against the disease.  
Another locus associated with T1D lies in the gene encoding for cytotoxic T lymphocyte-
associated protein 4 (CTLA-4), located in the IDDM12 region which is responsible for 
modulating immune responsiveness50. As with other regions, the risk association of allelic 
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variants in the CTLA-4 region is not exclusively confined to T1D, but has been replicated in 
several other autoimmune disorders, such as rhemautoid arthritis (RA)51, systemic lupus 
erythematosus (SLE)52 and multiple sclerosis (MS)53.  
Allelic variation in the interleukin (IL)-2 receptor-" gene (IL2RA)54 and PTPN22, which 
encodes the lymphoid protein tyrosin phosphatase55 are relatively new members of the T1D 
susceptibility gene set. 
 
Table 1. Type 1 diabetes risk associated with HLA-DR and HLA-DQ haplotypes.  
 
 
 
 
2.2.2 Epidemiology 
T1D has historically been considered a disorder predominantly of children and young adults; the 
disease is commonly referred to as juvenile diabetes because of its peak expression between ages 
10-14. However, several studies, conducted in the mid-90’, support a different model in which 
the disease can occur at any age37, 56. Additionally, the same studies found that 5-30% of adults 
patients initially diagnosed with type 2 diabetes actually had T1D, pointing a misclassification 
issue for the disease. 
  11 
Disease onset generally occurs before the age of 30, commonly peaking around puberty 
(e.g. 10-14), with the peak age of onset being somewhat earlier in girls than in boy34.  
The incidence of T1D varies by age group. The incidence of childhood-onset T1D in the 
age group 0-14 years varies more than 100-fold worldwide, with Finland and Sardinia (Italy) 
having the highest rates (>40 and 37.8/105, respectively), whereas the lowest rates have been 
reported from Venezuela (0.1/105) and China (0.1-4.5/105), with other Asian countries displaying 
a low frequency34,35. In accordance with the European ancestry of much of their population, the 
USA, Canada, Australia and New Zealand have high to very high T1D incidence rates.  
According to the America Center for Disease Control, the prevalence of T1D for 
residents of United States aged 0-19 years is 1.7/1,000. T1D incidence has been globally rising in 
the past decades, by as much as a 5.3% annually in the United States. If present trends continue, 
doubling of new cases of T1D in European children younger than 5 years is predicted between 
2005 and 2020, and prevalence of cases in individuals younger than 15 years will rise by 70%57 
characteristic of a shift towards an earlier age58. On this matter, The Diamond Study Group – in a 
study published in 2006 - commented that whatever event triggers the onset, is increasingly 
affecting susceptible individuals.  
 
 
2.3 Players of the inflammation process during T1D 
 
T1D is a chronic disease characterized by disruption of glucose homeostasis and by concomitant 
metabolic abnormalities as the result of insulin deficiency secondary to progressive autoimmune 
destruction of the insulin-producing pancreatic beta cells59.  
Although T cells are recognized to play a central role in the autoimmune destruction of 
the insulin-producing beta-cells 60, recent studies indicate that components of the innate immune 
system, including natural killer cells, monocytes, and inflammatory mediators have a much 
broader role in the pathogenesis of T1D and associated vascular complications than previously 
recognized61-64. The primary role of monocytes in the early stages of T1D pathogenesis65 has 
been demonstrated by showing that these cells are the first to accumulate in the pancreatic islets 
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of pre-diabetic BB rats66. Subsequent T and B lymphocyte infiltration is dependent upon prior 
monocyte invasion of the islets66, suggesting that monocytes and secreted inflammatory 
mediators might contribute to the early induction and amplification of the autoimmune assault 
against the pancreatic beta-cells67.  
A more generalized inflammatory response, with activation of monocytes and presence of 
oxidative stress has been found in the peripheral circulation of T1D patients. This inflammation 
is characterized by elevation of plasma levels of several inflammatory biomarkers, such as 
interleukin (IL)-1#, IL-6, IL-8, tumor necrosis factor(TNF)-", and C-reactive protein. Such 
inflammatory reactions have been detected both in recently diagnosed T1D children as well as in 
adult T1D patients well after the onset of diabetes68-73. These findings demonstrate that a 
generalized inflammatory response is present already in the very early stages of diabetes74, 75. 
Many of the reported inflammatory changes are detected at the level of monocytes, which show 
up-regulation of the adhesion molecule CD11b (Mac-1)75 and have aberrant constitutive and 
lipopolisaccharide (LPS)-stimulated expression of cyclooxygenase (COX)-2, a defect that may 
predispose to a chronic inflammatory response in T1D64,76. The vascular endothelium represents 
a likely target of this inflammatory response by inducing endothelial cell activation, alteration of 
endothelial function, and monocyte adherence eventually leading to overt vascular damage in the 
later stages of T1D.  
Indeed, inflammation is now considered a major component in the development of T1D-
associated vascular dysfunction71,77-79. It is therefore important to understand the origin of the 
inflammatory response characterizing T1D, since therapeutic strategies to decrease inflammatory 
activity in T1D will likely improve endothelial function. In particular, it is difficult to decide to 
what extent the inflammatory state is a primary pathogenic event contributing to the 
development of T1D or if it is the response to a metabolic derangement, i.e., a situation of poor 
glycaemic control and insulin-deficiency present at the early stages of the disease75, 80. In the first 
case, the inflammatory state should precede overt diabetes and in this context the study of pre-
diabetic subjects (i.e., autoantibody-positive individuals) should be characterized in respect to the 
inflammatory state.  
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2.4 Function of the endothelium layer in the vascular system 
Endothelial cells form a continuous dynamic layer of the blood vascular system that operates to 
deliver blood-borne nutrients and necessary levels of oxygen into tissues and, at the same time, 
to remove waste81. The endothelial cell lining is continuously exposed to a variety of 
biomechanical forces and stimuli and is thereby designated to be the homeostatic organ for the 
regulation of vascular tone and structure82. In addition, the endothelium has a regulatory role on 
leukocyte-endothelium interactions, leukocyte extravasation and subendothelial accumulation, 
all important events in the inflammatory cascade underlying vascular damage83.  
Chronic exposure of endothelial cells to insults and stressors shifts the normal endothelial 
function to a pathological degree, called endothelial dysfunction83. Endothelial dysfunction refers 
to a condition in which the ability of the endothelium to properly maintain vascular homeostasis 
is impaired84. Several pathological conditions have been identified as potential risk factors for 
the development of endothelial dysfunction, such as hypertension85, chronic renal failure86, T1D 
and T2D87,88, sedentary life style89, and smoking90. These observations suggest that the 
pathophysiology of endothelial dysfunction is complex and involves multiple mechanisms.  
  
2.5 T1D as a risk factor for the development of endothelial dysfunction  
Diabetes is a well-established risk factor for vascular diseases. Patients with T1D exhibit 
an increased susceptibility to develop a wide range of vascular complications, including 
microangiopathy and atherosclerosis, which account for the majority of deaths and disability in 
diabetic patients88. Diabetes causes vascular compromise secondary to endothelial dysfunction. 
A major hallmark of diabetes is an abnormally elevated blood glucose level, i.e. hyperglycemia, 
which is one important factor causing endothelial dysfunction in diabetes.  Acute (i.e., spike of 
hyperglycemia after a meal) and prolonged exposure of endothelial cells to high blood glucose 
are toxic to endothelial cells because they trigger massive changes in cellular phenotype, state of 
activation, metabolism and physiology. High glucose can exert a direct toxic effect on 
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endothelial cells or through the generation of intermediate products such as advanced glycation 
end-products (AGE)9,11,91,92. These changes are initially characterized by modification of 
endothelial cell function, such as by an increased vascular tone and permeability due to an 
impaired bioavailability of vasodilator factors such as nitric oxide and of vasoconstrictor factors 
such as endothelin (ET)-193. High glucose exposure also modulates availability of permeability 
factors such as vascular endothelial growth factor (VEGF)94.  
A second sign of endothelial dysfunction is the modification of cell molecule expression 
on the surface of endothelial cells. These molecules are essential for leukocyte-endothelium 
interaction, the first step in atherosclerosis plaque formation. Generally, these adhesion 
molecules, such as VCAM-1, intercellular adhesion molecules(ICAM)-1, and selectins (L-
selectine; or P-selectine), are expressed at low levels on endothelial cells and are up-regulated 
upon cellular activation, such as after exposure to high glucose or inflammation. Activated 
endothelial cells also increase secretion of certain pro-inflammatory cytokines, such as IL-6, IL-8 
and MCP-1, which are pivotal in initiating leukocyte interactions with endothelial cells and their 
subsequent recruitment in the subendothelial layer (Figure 3)95. The migrated monocytes 
phagocyte oxidize-low density lipoprotein(LDL), become foam cells and keep secreting 
inflamamtory mediators that maintain inflammation by recruiting more immune cells from the 
bloodstream to the vessel wall. In the meantime, smooth muscle cells proliferate and migrate 
from the media to the intima of the vessel wall where the new atherosclerotique plaque is 
developing. IL-8 and MCP-1 are usually found in human atherosclerotic plaques96. 
Simultaneously, adipocyte cells are also recognized to secrete circulating cytokines (adipokines) 
such as IL-6, tumor necrosis factor-alpha, leptin and plasminogen activator inhibitor(PAI-1), 
exacerbating the on-going vascular inflammation in the vessel wall of diabetic patients9,97.  
Additional players in the pathogenesis of hyperglycaemia-induced endothelial 
dysfunctions are reactive oxygen species (ROS). Hyperglycaemia increases oxidative stress and 
up-regulates the antioxidant enzyme machinery23. It has been shown that hyperglycaemia-
induced generation of ROS in endothelial cells occurs mainly through a NAD(P)H oxidase-
dependent mechanism. NAD(P)H oxidase is an enzymatic complex made up by several subunits 
localized in the cytoplasm and plasma membrane. Specifically, NAD(P)H oxidase is composed 
by 2 membrane subunits (p22phox and gp91phox) and 4 cytosolic subunits (p40phox, p47phox, 
  15 
p67phox and Rac-1).  In a scenario of hyperglycaemia, NAD(P)H oxidase is stimulated and the 
cytosolic subunits translocate from the cytosol to the plasma membrane to induce ROS 
production98. Excessive ROS production is toxic to endothelial cells and leads to decreased 
cellular proliferation99 and acceleration of the apoptotic process. One of the mechanism(s) 
underlying ROS toxicity in the endothelium involves activation of transcription factors such as 
NF-!B and activating protein(AP)-191,101-103, which ultimately lead to activation of genes that 
increase production of inflammatory mediators and inflammatory responses in general. Increased 
oxidative stress is observed in peripheral blood monocyte from T1D patients suffering from 
microvascular complications compared to those without microvascular complications, as 
demonstrated by elevated levels of nitrotyrosine, monocyte superoxide anion,71 DNA and protein 
oxidation104,105. Inflammation is now considered a major component in the endothelial 
dysfunction underlying vascular complications in T1D. 
 
2.6 Critical steps in vascular damage during T1D 
As shown in Figure 2, the endothelial dysfunction gravitates on the altered behavior of the cells 
of the artery wall, the endothelial cells and smooth muscle cells, and inflammatory leukocytes 
that join them in the arterial intima during the atherogenic process. Endothelial cells play an 
active role in the recruitment of inflammatory cells into the vessel wall, by producing cytokines 
and expressing cellular adhesion molecules (Fig. 2) (i.e. VCAM-1), and secretion of 
inflammatory cytokines as Il-8 and MCP-1.  
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Figure 3. Endothelial dysfunction during atherosclerosis in diabetes. Endothelial cells play an active role in the 
recruitment of inflammatory cells into the vessel wall, by producing cytokines and expressing cellular adhesion 
molecules (1) (i.e. VCAM-1, vascular cell adhesion molecule-1) and secretion of inflammatory cytokines as Il-8 and 
MCP-1. Subsequently, leukocytes will migrate to the subendothelial space, and will phagocyte oxidize-LDL, 
becoming foam cells (2). At the same time, smooth muscle cells proliferate and migrate (3) from the media to the 
intima of the vessel wall where a new atherosclerotique plaque is developing.   
 
 
These events will capture leukocytes (i.e. monocyte) and assist their passage into the sub-
endothelial space. Subsequently, leukocytes migrate to the subendothelial space, phagocyte 
oxidize-LDL and become foam cells. Smooth muscle cells proliferate and migrate from the 
media to the intima of the vessel wall where the new atherosclerotique plaque is developing.  
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3.0  MATHERIALS AND METHODS 
3.1 EFFECT OF C-PEPTIDE ON ENDOTHELIAL DYSFUNCTION DURING 
HYPERGLYCAEMIA 
3.1.1 Cell Cultures 
Human Aortic Endothelial Cell (HAEC) were obtained from Lonza (Lonza Bioscience 
Walkersville Inc., Walkersville, MD) and grown into 75 cm2 culture flasks (250,000/flask) 
(Corning Incorporated, Corning, NY, USA) at 37°C, 5% CO2 in the presence of EBM-2 
supplemented with EGM SingleQuots (Lonza) containing FBS (2%), hydrocortisone (0.04%), 
human fibroblast growth factor (0.4%), vascular endothelial growth factor (0.1%), R3–insulin –
like growth factor (0.1%), ascorbic acid (0.1%), heparin (0.1%), human epidermal growth factor 
(0.1%), gentamicin sulfate amphotericin-B (0.1%). EBM-2 contains 5.6 mmol/L glucose. Fresh 
EBM-2 was replaced every 2-3 days, and HAEC were used at passage 2-6.  
Human Umbilical Artery Smooth Muscle Cell (UASMC) and Human Aortic Smooth 
Muscle Cell (AoSMC) were obtained from Lonza  and grown into 75cm2 cell culture flasks 
(Corning Incorporated, NY, USA) at 37°C, 5% CO2 in the presence of Smooth Muscle Cell 
Basal Medium-2 (SMGM-2) (Lonza) additioned with 5% of FBS, 0.1% of antibiotics GA-1000 
(gentamicyn, amphotericin B), 0.2% of human basic fibroblastic growth factor (hFGF-b), 0.1% 
insulin, and 0.1% of human epidermal growth factor (hEGF) (Cambrex Bio Science). Cells were 
used at passage 4 to 10 for the experiments110. 
Human monocytic U-937 cells were purchased from the American Type Culture 
Collection (Rockville, MD) and grown in complete RPMI 1640 (Lonza Walkersville Inc, 
Maryland, USA) supplemented with 10% FBS, 100%l/mL streptomycin, 100IU/mL penicillin, 
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250ng/mL fungizone, 1mmol/L Sodium Pyruvate and 10mmol/L HEPES (all from Gibco 
Invitrogen, Carlsband, CA) in T75 cm2 flasks (Corning, NY, USA) at 37°C, 5% of CO2.  
 
 
3.1.2 IL-8 and MCP-1 detection in culture supernatant by ELISA 
HAEC were maintained in 6-well plates (50,000/well) (Corning) in the presence of EBM-2 
(Cambrex) until 80-90% confluent. On the day of the experiment, medium was replaced with 
fresh EBM-2 containing either 5.6 mmol/L or 25 mmol/L glucose (Sigma). Human C-peptide 
(Sigma) (0.5 nmol/L) was added to the high glucose medium. HAEC were also exposed to the 
NF-!B inhibitor PDTC (10 µM) (Sigma). HAEC were incubated at 37°C, 5% CO2 for 4 hours. 
Supernatant was collected and kept at -20ºC until tested by ELISA (Quantikine®, R&D Systems, 
MN, USA). Three independent experiments were performed. In each experiment, each condition 
was tested in triplicate. Concentration of the chemokines (pg/mL) was assessed by calculating 
values according to the values obtained in the standard curve. Data from three separate 
experiments were averaged.  
3.2 DETECTION OF VCAM-1 
3.2.1 RT-PCR  
HAEC confluent monolayers were grown into 75 cm2 culture flasks (250,000/flask) (Corning) 
and stimulated with 25 mmol/L glucose (high glucose condition) (Sigma, St. Louis, MO) in the 
presence or absence of physiological concentrations of human C-peptide (Sigma) (0.5 nmol/L 
and 1nmol/L)106 for 24 hours at 37°C, 5% CO2. HAEC cultured in regular EBM-2 were used as a 
baseline for VCAM-1 expression. As a positive control, HAEC were exposed to human 
recombinant TNF-" (10 ng/mL) (R&D System, Inc., MN, USA), which up-regulates VCAM-1. 
As a control for C-peptide activity, C-peptide (1 nmol/L) was heat-inactivated by boiling it for 1 
hour. RNA extraction was performed using the RiboPureTM-Blood kit (Ambion, Texas, USA). 
1 µg of RNA was used for RT-PCR using Oligo(d)T (RETROscript, Ambion). VCAM-1 was 
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amplified from 1 µl of cDNA using the following oligonucleotides: sense 5’-
CCCTTGACCGGCTGGAGATT-3’, and antisense 5’-
CTGGGGGGCAACATTGACATAAAGTG-3’107. TITANIUMTM Taq PCR Kit (Clontech 
Laboratories, Inc. Mountain View, CA) was used for PCR amplification. PCR conditions were: 
94ºC for 40s, 60ºC for 30s, and 68ºC for 3min. Amplification of GAPDH was performed as 
internal control using the following oligonucleotides: sense 5’-
ACCACACAGTCCATGCCATCAC-3’, and antisense 5’-TCCACCACCCTGTTGCTGTA-
3’107.  PCR conditions were: 94ºC for 40s, 58ºC for 30s, and 68ºC for 3 min. After 30 cycles, 
PCR products were detectable by electrophoresis. Three independent experiments were 
performed. Densitometry was performed with UN-SCAN-IT gel software (Silk Scientific, Orem, 
UT). Data were averaged and expressed as means ± SD. 
 
3.2.2 Surface staining by flow cytometry  
 
HAEC were maintained in 6-well plates (50,000/well) in the presence of EBM-2 until 80-90% 
confluent. On the day of the experiment, medium was replaced with 2 mL of fresh EBM-2 
containing either 5.6 mmol/L or 25 mmol/L glucose (Sigma). Human C-peptide (Sigma) (0.5 and 
1 nmol/L) was added to the high glucose medium and cells were kept at 37°C, 5% CO2 for 24 
hours. Heat-inactivated human C-peptide (1 nmol/L) was used as control. HAEC were also 
exposed to human recombinant TNF-" (10 ng/mL) (R&D System). After 24 hours, HAEC were 
harvested and assayed for VCAM-1 expression. Determination of VCAM-1 expression was 
performed on PFA-fixed HAEC monolayers following a methodology shown to preserve single 
cell integrity, which is a prerequisite for flow cytometric determination of surface adhesion 
molecules108. Briefly, after incubation of the cells in the different conditions, HAEC were 
washed with PBS (Gibco BRL, Life Technologies Inc., Rockville, MD) and fixed with 0.5% 
cold PFA. Cells were then stained for 30 minutes with saturating concentration of PE conjugated 
anti-human mAb to CD106 (VCAM-1) (BD Pharmigen, San Diego, CA). A PE isotype control 
(BD Pharmigen) was added at the same concentration of the specific mAb. HAEC were washed, 
trypsinized and the pellet fixed in cold 0.5% PFA and run on a Becton Dickinson FACSCalibur 
(Becton Dickinson, San Jose, CA). For each sample, at least 5,000 events were acquired.  
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Data were analyzed by CELLQuest software (Becton Dickinson). Dot-plot graphs of SSC versus 
FSC were drawn, and a gate was created around the HAEC. Within this gate, HAEC were 
analyzed for cells positive for CD106. Lower limits for antibody positivity were determined 
using the negative isotype control. Fluorescence was measured using a log10 scale. Results were 
expressed as MFI (brightness of fluorescence) of the positive cells for CD106. Since mAb to 
CD106 was used at saturating concentration, the MFI of the antibody binding could be used as a 
semi quantitative measure of the amount of antigen detected. Three sets of independent 
experiments were performed. Within each experiment, each condition was tested in triplicate. 
Data were averaged and expressed as means ± SD. 
 
3.3 MONOCYTE ADHESION ASSAY 
HAEC confluent monolayers were grown on 48-well plates (12,000/well) (Corning) and 
stimulated with EBM-2 (Cambrex) with 25 mmol/L glucose in the presence of absence of 0.5 
nmol/L of human C-peptide for 4 hours. Heat inactivated human C-peptide (0.5 nmol/L) was 
used as control for C-peptide activity. HAEC were also exposed to human recombinant TNF-
" (10 ng/mL) (R&D System). Human monocytic U-937 cells were purchased from the American 
Type Culture Collection (Rockville, MD) and grown in RPMI 1640 (Cambrex) containing 10% 
FCS, 100 %l/mL streptomycin, 100 IU/mL penicillin, 250 ng/ml fungizone, 1 mmol/L Sodium 
Pyruvate, 10 mmol/L HEPES (all from Gibco Invitrogen, Carlsband, CA) at 37°C, 5% of CO2. 
On the day of the experiment, medium was removed from each well, cells were washed with 
PBS and fresh medium containing U-937 cells (1 x 106 cells/mL) was added to each well and 
incubated for 1 hour at room temperature on a rocking plate. Non-adherent U-937 cells were 
removed and adherent cells fixed in 1% glutaraldehyde. To determine the number of adherent 
cells, three random 40x field/well were counted and averaged by a blinded investigator, avoiding 
areas of non-confluence and cell clusters. Three experiments were performed. Within each 
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experiment, each condition was tested in triplicate. Results were averaged and showed as means 
± SD. 
3.4 WESTERN BLOTTING ANALYSIS 
HAEC were cultured in 75 cm2 culture flasks (250,000/flask) in the presence of 25 mmol/L 
glucose alone or in combination with C-peptide (0.5 nmol/L) for 24 hours. Heat-inactivated C-
peptide (0.5 nmol/L) was used as control. Cells were harvested at 4 and 24 hours and pretreated 
with 25 %l of protease inhibitor cocktail (Pierce, Rockford, IL). Nuclear and cytoplasmic 
fractions were separated using NE-PER® Nuclear and Cytoplasmic extraction kit (Pierce). 
Protein content of the extract was measured using a bicinchoninc acid assay kit (Pierce 
Biotechnology). A minimum of three independent experiments were performed. NF-!B 
immunoblot was performed as previously described109 with 10 %g of nuclear protein extracts. 
Densitometry was performed with UN-SCAN-IT gel software (Silk Scientific). For each set of 
data, a minimum of three experiments was performed. Data were averaged and expressed as 
means ± SD. Activation of the NF-!B p50 subunit was detected on 3 %g of nuclear protein 
extracts using a EZ-DetectTM Transcription Factor Kit (Pierce Technology). For each set of data, 
a minimum of three experiments was performed. Data were averaged and expressed as means ± 
SD. 
For Bcl-2 and cleaved caspase-3 proteins detection, HAEC were grown into T-75cm2 
flasks and exposed overnight to the treatment conditions as above. For Rac-1 protein detection, 
HAEC were serum starved overnight before treatment for 30min. Cytosolic and membrane 
proteins were extracted using Qproteame Cell Compartment kit (QIAGEN, Valencia, CA) and 
protein content was measured using a bicinchoninic acid assay kit (Pierce Biotechnology). 
Aliquots of protein extracts (30%g) were subject to immunoblot ananlysis using rabbit polyclonal 
anti-Rac-1 (1:1000), anti-cleaved caspase-3 (1:500), anti-Bcl-2 antibodies (all from Cell 
Signaling Technology, Danvers, USA) and mouse monoclonal anti-#-actin antibody (1:10,000; 
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Sigma). Densitometry was performed with UN-SCAN-IT gel software (Silk Scientific, Orem, 
UT). A minimum of three independent experiments was performed. 
3.5 COMMON EXPERIMENT TREATMENT FOR VASCULAR SMOOTH 
MUSCLE CELLS 
SMGM-2 containing 25mmol/L glucose (Sigma Chemical S. Louis, MO, USA) was used as a 
high glucose condition in all the experiments, while basal SMGM-2, which contains 5.6mmol/L 
glucose, was used as normal glucose control. In all experiments, cells were serum-deprived for 
24 hours with SMGM-2 containing 1% FBS and 0.1% antibiotics GA-1000. Cells were then 
replaced with SMGM-2 containing 25mmol/L glucose in the presence or absence of human C-
peptide (0.5 and 1nmol/L) (Sigma Chemical) for 48 hours. Basal SMGM-2 containing 
5.6mmol/L glucose was used as control. Insulin was not added to the culture medium. The 
effects of two different NF-!B-inhibitors, such as (E)-3-(-4-Methylphenylsulfonyl)-2-
propenenitrile (1µM) (Bay11-7082; Sigma) and pyrrolidine dithiocarbamate (PDTC, Sigma) 
(20µM) were also tested in VSMCs. These NF-!B-inhibitors were added to SMGM-2 with 
25mmol/L glucose for 48 hours. Separate sets of experiments were performed in which C-
peptide (0.5 and 1nmol/L) was added to medium containing normal glucose. Purity of C-peptide 
was &95% as assessed by the manufacturer by HPLC evaluation. Human scrambled C-peptide 
(Sigma-Genosys, Texas, USA) was used as a control. The scrambled C-peptide has an identical 
amino acid composition to that of the human C-peptide, but the sequence was randomized (110).  
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3.6 PROLIFERATION STUDY 
3.6.1 Cell counting  
33,000 UASMC/well were seeded in 6-well plates (Corning Incorporated) and left overnight in 
an incubator at 37°C, 5% CO2. Cells were then serum-deprived and exposed to the indicated 
treatment conditions and then counted using a Neubauer Hemocytometer (Hausser Scientific, 
Horsham, PA), as previously published11,112. 
 
 3.6.2 BrdU measurement 
Proliferation of VSMCs was evaluated by uptake of bromo-2’-deoxy-uridine (BrdU) using an 
ELISA kit (Roche Diagnostic, Manheim, Germany) following manufacturer’s instructions. 
Briefly, UASMC and AoSMC were seeded (6x104cells/100µL) in 96 well flat-bottomed plate 
(FALCON® Becton Dickinson and Company, Franklin Lakes, NJ) and kept them at 37°C, 5% 
CO2 overnight. Cells were then exposed to the indicated treatment conditions in the presence of 
10µmol/L of BrdU. Each condition was tested in triplicate. Results were expressed as 
proliferative response (fold induction versus 5.6mmol/L) and final data averaged (mean values ± 
SD). 
 
3.6.3 Ki-67 staining 
As another technique to assess VSMC proliferation, we used Ki-67 immunofluorescence staining 
for proliferating cells. UASMC were seeded into a glass bottom culture dish (35 mm diameter, 
poly-d-lysin coated) (MatTek Corporation, Ashland, MA) (~100,000 cells/dish) and then 
cultured following treatment conditions. Cells were permeabilized with 0.02% of Triton-X100 
(Sigma), fixed with 2% paraformaldehyde (PFA) (USB Corporation, Cleveland, OH, USA) and 
stained with a monoclonal mouse anti-human Ki-67 primary antibody overnight (1:100, 
DakoCytomation, Denmark). A carboxymethylindocyanine 3(Cy3)-conjugated goat anti mouse 
secondary antibody (1:500, Jackson Immuno Research Lab INC. West Grove, PA) was then 
added for 1 hour. DAPI stain (Molecular Probes, Eugene, OR) was used to stain the nuclei. 
Images were recorded with a confocal laser-scanning microscope (Nikon, Eclipse E800, Japan). 
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The number of Ki67+ cells was counted in 5 different fields per dish by one of the investigator 
blind to the study. A Ki67-labeling index was calculated by dividing the number of Ki67+ cells 
by the total number of cells in each of the 5 fields. An averaged Ki-67-labeling index (±SD) was 
then obtained for each section. Four different independent experiments were performed.  
 
 
3.7 IMMUNOFLUORESCENCE ANALYSIS FOR NF-kB P65 
 
UASMC were seeded into a glass bottom culture dish (~100,000 cells/dish) (MatTek 
Corporation). After the indicated treatments, cells were fixed with 2% PFA (USB Corporation), 
and stained with a rabbit polyclonal primary antibody against NF-kB p65 (1:150, Santa Cruz 
Biotechnology, Inc) at 4°C overnight. A carboxymethylindocyanine 3(Cy3)-conjugated goat 
anti-rabbit secondary antibody (1:500, Jackson Immuno Research Lab INC.) was then added for 
1 hour, in the dark, at room temperature. DAPI stain (Molecular Probes, Eugene, OR) was used 
to stain the nuclei. Fluorescence staining was evaluated using Nikon, Eclipse E800 
epifluorescence microscope connected to a digital camera and interfaced with a computer. 
3.8 DETECTION OF APOPTOSIS IN ENDOTHELIAL CELL 
3.8.1 Treatment conditions 
In all experiments, HAEC were exposed to regular EBM-2 media, or high glucose medium, or 
high glucose medium with either C-peptide (Phoenix Pharmaceuticals, Burlingame, CA) or 
scrambled C-peptide (Sigma-Genosys, Texas, USA) (10nmol/L) for a time period ranging from 
30 min to 12-48 hours, as specified in each experiment, at 37°C in a humidified atmosphere of 
95% air and 5% CO2. In experiments to detect Rac-1 GTPase activity, Rac-1 mRNA expression, 
Rac-1 protein levels, and NAD(P)H oxidase activity, hEGF was removed from the EBM-2 media 
to avoid aspecific Rac activation. 
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3.8.2. Detection of cytoplasmic histone-associated-DNA fragments 
HAEC were seeded in 96-well plates overnight and the next day treated as above for 48 hours. 
Apoptosis was detected by using Cell Death Detection ELISAPLUS (Roche Diagnostics GmBH, 
Mannheim, Germany), which detects cytoplasmic histone-associated-DNA-fragments after 
induced-cell death. Results were expressed as absorbance raw data and percentage of apoptosis 
versus high glucose condition. Three different experiments were run in which each condition was 
tested in triplicate. 
 
3.8.3 Caspase-3 enzyme activity 
HAEC were maintained in 96-well plate until confluency, and exposed to treatment conditions as 
above overnight. Caspase-3 activity was assessed using Caspase-3 Activity Assay Kit following 
manufacturer’s instructions (Calbiochem, EMD Chemicals, Gibbstown, NJ). Results were 
expressed as caspase-3 activity fold induction versus normal glucose condition.  
 
3.9 DETERMINATION OF REACTIVE OXIGEN SPECIES 
 
3.9.1 Measure of intracellular ROS 
HAEC  (50,000/well) were seeded in 6-well plates and treated as specified above overnight. 
Intracellular hydrogen peroxide (H2O2) production was monitored by flow cytometry using CM-
H2-DCFDA (Molecular Probes, Invitrogen, cat. C6827), a membrane-permeable indicator for 
ROS that is non-fluorescent until removal of the acetate groups by intracellular esterases and 
oxidation occurs within the cell. CM-H2-DCFDA was added to each well at a final concentration 
of 10µmol/L in phosphate buffer saline (PBS) (Gibco). Cells were put in the incubator for 30min 
to allow uptake of the dye. After cellular detachment, cells were collected in 12x75mm flow 
tubes (Falcon), and centrifuged at 1,000rpm for 5 min. Cells were resuspended in freshly 
prepared regular EBM-2, or high glucose medium, or high glucose with C-peptide (10nmol/L) 
and immediately run at the flow cytometer (time 0) (Becton Dickinson FACSARIA II, BD 
Biosciences, San Jose, CA). HAEC were maintained at 37°C and intracellular ROS production 
monitored every hour until 5 hours. Results are expressed as mean fluorescence of CM-H2-
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DCFDA in HAEC.  At least 4 experiments were run in which each condition was tested in 
duplicate. 
 
3.9.2 NADPH oxydase activity detection  
NADPH oxidase activity was measured in cells using lucigenin-derived chemiluminescence, as 
described previously113. HAEC were seeded into T-25cm2 flasks, serum starved overnight and 
exposed to treatment conditions as above for 30 minutes. Pre-treatment for 2 hours with the 
pharmacological inhibitors of NAD(P)H oxidase apocynin (10µM; Sigma) and 
diphenyliodonium (DPI) (100µM; Sigma) were tested as well. After detachment from the flasks, 
cells were resuspended in Krebs–Henseleit buffer (10 mmol/L glucose, 0.02 mmol/L Ca-
Tritriplex, 25 mmol/L NaHCO3, 1.2 mmol/l KH2PO4, 120 mmol/L NaCl, 1.6 mmol/L 
CaCl2'2H2O, 1.2 mmol/L MgSO4'7H2O, and 5 mmol/L KCl, pH 7.4) and seeded in white 96-
well plates (105 cells/well). Superoxide anion production was measured in the presence of 
lucigenin, (5 %mol/L, incubated for 20 min). The reaction was started by the addition of NADPH 
(100 %mol/L), and the relative light units (RLU) luminescences were measured over a period of 
30 minutes in a Victor3 multi-well reader (PerkinElmer, Shelton, USA). Three experiments were 
performed in which each condition was tested in quadruplicate.  Results were expressed as 
percent of NAD(P)H oxidase activity.   
 
3.9.3 Measure of mRNA expression by qRT-PCR  
HAEC were grown into T-75cm2 flasks, then were serum starved overnight and exposed to 
treatment conditions as above for 30 minutes. Total RNA was isolated using a commercial kit 
(RNAqueous-4PCR kit; Ambion, Austin, TX) and quantified by spectrophotometry. One 
microgram of RNA was reverse transcribed to cDNA (5 min at 65°C, 50 min at 50°C and 5 min 
at 85°C) using oligo(dT) primers (Invitrogen, Carlsband, CA). Using the LightCycler system 
(Roche Diagnostics) according to the manufacturer’s instruction, quantitative real time PCR was 
performed using the following primers: Rac-1 sense 5’ AGGAAGAGAAAATGCCTG-3’ and 
antisense 5’-AGCAAAGCGTACAAAGGT-3’ and housekeeping gene GAPDH sense 5’-
TCGGAGTCAACGGATTTGGTCGTA-3’ and antisense 5’- 
TGGCATGGACTGTGGTCATGAGTC-3’114. Aliquots of the cDNA were loaded into capillary 
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tubes and amplified for 40 cycles. The PCR products were further analyzed by agarose gel 
electrophoresis to confirm the correct length of the amplified products. Rac-1 data were 
normalized using GAPDH housekeeping gene and results were expressed as fold induction 
versus normal glucose condition. 
 
3.9.4 Assessment of Rac-1 GTPase activity 
HAEC were grown into T-75cm2 flasks until confluency, serum starved overnight and exposed 
to treatment conditions as above for 30 minutes. Rac GTPase activity was measured in 10µg of 
cell lysates using a commercially available Rac G-LISATM Activation Assay kit which measures 
the GTP form of Rac-1 from HAEC lysates following manufacturer’s instructions (Cytoskeleton, 
Inc, Denver, CO). At least 4 experiments were run in which each condition was tested in 
duplicate. Results are expressed as GTPase activity-fold induction compared to normal glucose 
condition. 
3.10 CITOKINE SECRETION STUDY IN U-937 MONOCYTE 
3.10.1 Luminex Assay Analysis 
U-937 cells (50,000 cells/well/mL) were seeded in 24-well plates in presence of RPMI-1640 
supplemented with 30mmol/L glucose and stimulated with 0.5ng/µL of LPS from E.Coli 
(E25:B55) in the presence or absence of 1µmol/L C-peptide (Sigma Chemical, St. Louis, MO) 
for 24 hours at 37°C, 5% of CO2.  A randomized version of the full-length C-peptide containing 
the same amino acid residues but randomly ordered (scrambled C-peptide; Sigma Genosys), was 
used as control at the same concentration of the C-peptide. Supernatant was collected in 1.5mL 
cryovials and stored at -20°C until tested for cytokine concentration. Luminex multiplex assays 
were used to assess levels of IL-6, IL-8, macrophage inflammatory protein (MIP)-1" and MIP-
1# (Millipore Human Cytokine kit, Millipore Corp. Billerica, MA) in the culture supernatants of 
LPS-stimulated U-937 cells following manufacturer’s instructions. A minimum of 4 independent 
experiments was performed. Each condition was tested in duplicate. 
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3.10.2 Adhesion of U-937 monocytes to HAEC 
Human Aortic Endothelial Cells (HAEC) were purchased from Lonza and maintained in EBM-2 
media at 37°C, 5% CO2 as previously described. HAEC (200,000cells/well) were then seeded on 
48-well plates and grown until they reached 90% confluency. U-937 monocytes were exposed to 
low (5.6mmol/L), or intermediate (11mmol/L), or high glucose (30mmol/L) medium, in the 
presence or absence of C-peptide (2µmol/L) for 4 hours at 37°C, 5% CO2. As a positive control 
to induce adhesion, U-937 monocytes were stimulated with IL-1# (1ng/mL, Sigma Chemical) for 
4 hours at 37°C, 5% CO2. After the allotted time, U-937 cells were added on top of the HAEC 
for 1 hour at room temperature on a rocking plate. Non-adherent U-937 cells were removed by 
washing and adherent cells fixed in 1.25% glutaraldehyde. The number of adherent U-937 
monocytes was evaluated by counting five random 40X fields per well. At least three 
experiments were performed. Within each experiment, each condition was tested in triplicate.  
 
3.10.3 Immunoprecipitation of  I!B-" and Phosphorylated I!B-"  
Cytoplasmic extracts (50 µg) were incubated overnight at 4ºC with anti-I!B-" IgG (1:100). The 
samples were then treated with 10µl of protein A agarose beads (Sigma) for 2 h at 4ºC after 
which the samples were centrifuged and washed 5 times in PBS (Gibco). The beads were boiled 
in SDS-PAGE sample treatment buffer and electrophoresed on a 4-20% SDS-PAG as described 
above. The PVDF membranes were then blotted and incubated with either monoclonal P-I!B-" 
or I!B-" antibodies (both from Santa Cruz Biotechnology; 1:1000) followed by incubation with 
an anti-rabbit peroxidase secondary antibody (1:10,000, Jackson Laboratories, Bar Harbor, 
USA).  
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3.11 INTERNALIZATION OF C-PEPTIDE IN ENDOTHELIAL CELL (HAEC) AND 
SMOOTH MUSCLE CELLS (UASMC) 
3.11.1 Cell culture  
HAEC and UASMC were obtained from Cambrex (Cambrex Bioscience Walkersville Inc., 
Walkersville, MD) and grown into 75 cm2 flasks (Corning Incorporated, Corning, NY, USA) at 
37°C, 5% CO2 as previously described. HAEC were used at passage 2-6 and UASMC were used 
at passage 4-10. Unless differently specified, in all experiments HAEC and UASMC (~100,000 
cell/dish) were seeded on 35 mm diameter, poly-d-lysine coated MatTek plates (MatTek 
Corporation, Ashland,MA) and allowed to settle overnight at 37°C, 5% CO2 in their specific 
medium. Next day, cells were washed with fresh medium before starting with the specific 
experimental conditions. 
 
3.11.2 Preparation of AlexaFluor-labelled C-peptide and culture conditions   
Two AlexaFluor-labelled C-peptide probes were customized, one labeled with AlexaFluor488 
and the other with AlexaFluor546, and had them synthesized by Molecular Probes (Invitrogen 
Corporation, Carlsbad, CA). Unless differently specified, 1 µmol/L of AlexaFluor488- or 
AlexaFluor546-labelled C-peptide (Molecular Probes, Invitrogen Corporation) was added to 
each MatTek plate in serum-free medium. Cells were incubated at 37°C, 5% CO2 for the 
designated time. After incubation, fluorescent probe was discarded and cells were washed with 
fresh medium before analysis under a confocal microscope. The concentration of fluorescent 
probe corresponded to the minimum concentration of fluorescent probe that we were able to 
easily detect in our experimental system, and had also been previously used by other115.  
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3.12 LIVE-CELL CONFOCAL IMAGING 
3.12.1 Time course of C-peptide internalization 
Confocal fluorescence microscopy was performed using an Olympus Fluoview 300 Confocal 
Laser Scanning head with an Olympus IX70 inverted microscope (Melville, NY, USA).  
Cells were incubated with the fluorescent C-peptide probe for a minimum of 5 min and a 
maximum of 1 h. As a control for specificity of the staining, 1 µmol/L of free AlexaFluor488 
(cat.#A10235) or AlexaFluor546 fluorescent dye (cat.#A20002) (Molecular Probes, Invitrogen 
Corporation) was added to separate plates. Cells were studied in an “open” cell cultivation 
system at 37°C by live-cell confocal microscopy after 5 min, 10 min, 20 min, 30 min, and 1 h 
from uptake of the C-peptide probe. At least 8 independent experiments were performed, with a 
minimum of 6 MatTek plates with adherent cells each. 
 
3.12.2 Effect of temperature on AlexaFluor-labelled C-peptide internalization  
Cells were cooled at 4ºC in a fridge for 1 h and then incubated with the fluorescent C-peptide 
probe at 4ºC for 30 min. Uptake of the fluorescent probe by live-cells was studied under a 
confocal microscope. Cells were then incubated at 37°C, 5% CO2 for 1 h and analyzed again 
with a confocal microscope. At least 4 independent experiments were performed, with a 
minimum of 6 MatTek plates for each experiment. 
 
3.12.3 Inhibition of AlexaFluor-labelled C-peptide uptake by excess of unlabelled C-peptide 
Cells were incubated with either 30 µmol/L of unlabelled, native, C-peptide (Sigma) or 30 
µmol/L of scrambled C-peptide (Sigma Genosys) for 1 h at 37°C, 5% CO2. This latter peptide 
(purity of >95%) represents a randomized version of the native C-peptide containing the same 
amino acid residues but randomly ordered, as follows: 
ADQEVELGAPQSAGLGGSQLEPQGLGLVLGE. After 1 h of incubation, fluorescent C-
peptide probe was added for 30 min. Live-cells were then analyzed under a confocal microscope. 
Uptake of C-peptide in these cells was compared with uptake of fluorescent C-peptide in the 
absence of any pre-incubation with either unlabelled, native, or scrambled C-peptide.  
  31 
3.12.4 Uptake of AlexaFluor-labelled C-peptide in the presence of pharmacological 
compounds 
Cells were pre-treated for 30 min at 37°C, 5% CO2 with either Monodansylcadaverine (MDC;43 
µmol/l), which inhibits the clathrin-coated pit pathway, Filipin (5 µg/mL), which blocks 
caveolae pathway, Nocodazole (10 µmol/L), which disrupts microtubule assembly, or 
Cytochalasin D (30 µmol/L), which disrupts actin filaments. The dose and time of treatment for 
each compound, which showed no toxic effect, was determined experimentally on the basis of 
previous reports116-119. After 30 min, fluorescent C-peptide was added for 30 min and cells put 
back in the incubator. Cells were then examined under a confocal microscope. The response of 
cells to each condition was highly consistent with inhibition of C-peptide uptake with MDC and 
Nocodazole. We therefore analyzed the mean fluorescence per cell in only 3 cells/plate (total of 
9 cells) for each condition by using Olympus Fluoview 300 Software. Repeated Measures 
ANOVA was applied to determine statistical significance. 
3.13 SUB-CELLULAR ORGANELLES CO-LOCALIZATION STUDY 
3.13.1 Endosome transduction 
Cells were transduced with 500 µL of Organelle LightsTM Endosomes-GFP reagent (Invitrogen 
Corporation, cat.#010104), which target Rab5a, an early endosomal marker, following 
manufacturer’s instructions. The plates were incubated for 2 h on a plate shaker at room 
temperature. After removing the medium, 500 µL of 1:1000 dilution of enhancer was added to 
the cells and incubated at 37°C, 5% CO2 for 2 h. Cells were kept in the incubator for 2 days in 
fresh medium to allow expression of the fluorescence protein and then incubated with 
fluorescent C-peptide for 30 min before confocal microscopy analysis. At least 5 independent 
experiments were performed for each organelle, with a minimum of 6 MatTek plates with 
adherent cells each. 
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3.13.2 Immunohistochemistry of early endosomes  
HAEC (~100,000 cell/dish) seeded on MatTek plates (MatTek Corporation) were fixed with 
paraformaldehyde (PFA), and incubated with rabbit anti-human antibody to C-peptide (Millipore 
Corporation, Billerica, MA) together with a mouse anti-human monoclonal antibody to the early 
endosome antigen 1 (EEA1) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) for 2 h. 
Appropriate secondary antibodies were then applied. Cells were washed and imaged by using 
confocal microscopy. At least 4 independent experiments were performed, with a minimum of 6 
MatTek plates with adherent cells each. 
 
3.13.3 Isolation of endosomes and analysis of C-peptide content  
To identify early endosomes, we followed internalization of AlexaFluor488-conjugated human 
transferrin, a ligand known to enter the cells by clathrin-mediated endocytosis and a specific 
marker of early endosomes120 in the presence of AlexaFluor546-labelled C-peptide in UASMC 
in the incubator for 10 min. Endosomes were isolated from other sub-cellular compartments by 
centrifugation121 and an aliquote of both the pellet and the endosome-containing supernatant used 
to quantitate AlexaFluor488-transferrin and AlexaFluor546-C-peptide fluorescence spectra by 
using a scanning spectrofluorimeter. Repeated Measures ANOVA was applied to determine 
statistical significance. Three independent experiments were performed. 
3.14 STATISTICAL ANALYSIS 
Two-tailed paired t-test was used to assess differences between the different conditions tested by 
using GraphPad Prism 4 program (GraphPad Software, Inc. San Diego, CA). Values of p< 0.05 
were considered to be statistically significant. 
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4.1 ABSTRACT 
Aims: Endothelial dysfunction in diabetes is predominantly caused by hyperglycemia leading to 
vascular complications through overproduction of oxidative stress and activation of the 
transcription factor nuclear factor (NF)-!B. Many studies have suggested that decreased 
circulating levels of C-peptide may play a role in diabetic vascular dysfunction. To date, the 
possible effect of C-peptide on endothelial cells and intracellular signaling pathways are largely 
unknown. We therefore investigated the effect of C-peptide on several biochemical markers of 
endothelial dysfunction in vitro. To gain insights on potential intracellular signaling pathways 
affected by C-peptide, we tested NF-!B activation, since it is known that inflammation, 
secondary to oxidative stress, is a key component of vascular complications and NF-!B is a 
redox-dependent transcription factor. Methods: Human Aortic Endothelial Cells (HAEC) were 
exposed to 25 mmol/L glucose in the presence of C-peptide (0.5 nmol/L) for 24 hours and tested 
for expression of vascular cell adhesion molecule (VCAM)-1 by RT-PCR and flow cytometry. 
Secretion of interleukin(IL)-8 and monocyte chemoattractant protein (MCP)-1 was measured by 
ELISA. NF-!B activation was analyzed by immunoblotting and ELISA. Results: Physiologic 
concentrations of C-peptide impact high glucose-induced endothelial dysfunction by: a) 
decreasing VCAM-1 expression and U-937 cell adherence to HAEC; b) reducing secretion of IL-
8 and MCP-1; and c) suppressing NF-!B activation. Conclusions: During hyperglycemia, C-
peptide directly affects VCAM-1 expression , and MCP-1 and IL-8 secretion by HAEC through 
a reduced NF-!B activation. These effects suggest a physiologic anti-inflammatory (and 
potentially anti-atherogenic) activity of C-peptide on endothelial cells.  
 
 
4.2 INTRODUCTION 
 
It is well established that diabetic vascular disease is characterized by changes in small 
(microangiopathy) as well large vessels (macroangiopathy) with common biochemical changes 
in the tunica media. In the large vessels, the changes are supposed to increase the sucepibility to 
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atherogenic insults and thereby pave the way for an increased presence of atherosclerosis in 
patients with diabetes. In the small vessels, the disease principally affects the eye, kidney and 
heart and dysfunction, as a result of the diabetic state, contributes significantly to the morbidity 
associated with diabetes10.  
Diabetes causes vascular compromise secondary to endothelial dysfunction, measured by 
in vivo studies of flow-mediated vasodilation133 and increased circulating levels of biochemical 
markers, such as, but clearly not limited to VCAM-191. Generally, VCAM-1 is expressed at a 
low level on endothelial cells and is up-regulated upon cellular activation, such as the one 
observed after exposure to inflammatory stimuli or high glucose92. VCAM-1 binds to the 
leukocyte integrin "4#4 (also called Very Late Antigen-4; CD49d), and has a principal role in the 
early stages of monocytes adhesion to the vascular endothelium, one of the first steps in 
atherosclerosis plaque formation108. A major hallmark of diabetes is an abnormally elevated high 
blood glucose level (i.e., hyperglycemia) and hyperglycemia has been proposed as one factor 
causing endothelial dysfunction in diabetes. In endothelial cells, acute and chronic 
hyperglycemia works through ROS production91,104,105 that leads to activation of the transcription 
factor NF-!B 91,146 and ultimately the production of inflammatory mediators 101. 
In the unstimulated state, NF-!B exists in its canonical form as a heterodimer composed 
of p50 and p65 subunits bound to I!B. Upon activation, I!B is phosphorylated and degraded 
causing the release of p50/p65 components of NF-!B 93.  The active p50/p65 heterodimer 
translocates to the nucleus and initiates the transcription of a gamut of genes involved in the 
inflammatory response, such as pro-inflammatory cytokines, cell surface adhesion molecules, 
and chemokines, including IL-8 and MCP-1 91,95. IL-8 and MCP-1 expression is present in 
human atherosclerotic plaques 85,96 and participates in the development of atherosclerosis by 
recruiting monocytes into the subendothelial cell layer 95.  
It has been suggested that proinsulin C-peptide, may possess cytoprotective effects on the 
microvasculature during inflammatory events6. In line with this, it has been reported that T1D 
patients with circulating levels of C-peptide closer to the physiological level of 0.5 nmol/L2 or 
receiving whole pancreas29 or allogeneic islet transplantation30 show a reduced incidence of 
microvascular complications. The mechanisms underlying the beneficial effect of C-peptide on 
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vascular dysfunction in diabetes remains largely unknown. One study performed in vivo in a rat 
inflammatory model of vascular dysfunction, showed that a single i.v. dose of C-peptide 
significantly inhibited leukocyte-endothelium interaction via decreased expression of endothelial 
cell adhesion molecules17. Similar results were obtained in isolated ischemic and reperfused rat 
hearts, where addition of C-peptide attenuated polymorphonuclear cells adherence to the 
vascular endothelium18.  To date, no data are available on the effects of C-peptide on human 
endothelial cells exposed to the damaging insult of hyperglycemia, a common condition in 
diabetes.  
We therefore initiated a study on the direct effect of C-peptide testing VCAM-1 
expression, monocyte adherence, and secretion of IL-8 and MCP-1 by HAEC exposed to short-
term high glucose. Since activation of the transcription factor NF-!B is involved in these pro-
inflammatory responses, we also investigated the direct effect of C-peptide on nuclear 
translocation of the NF-!B subunits p50/p65 in HAEC. We hypothesized that physiologic 
concentrations of C-peptide protects HAEC from high glucose-induced cellular dysfunction by 
decreasing NF-!B activation thus inhibiting NF-!B-dependent genes, such as VCAM-1, IL-8 
and MCP-1 expression.  
 
4.3 RESULTS 
 
We observed that C-peptide is able to decrease the expression of the adhesion molecule VCAM-
1 on endothelial cells exposed to high glucose (25 mmol/L glucose). VCAM-1 expression and 
secretion was assessed by RT-PCR (Figure 4a-1c) and ELISA (Figure 5a) measurements after 4 
and 24h treatment with C-peptide. Heat inactivated C-peptide was used as a positive control. 
When C-peptide was added to low glucose medium (5.6 mmol/l glucose), it did not cause a 
significant change in VCAM-1 (Figure 5b) (107).  
To determine whether C-peptide-induced inhibition of VCAM-1 was associated with a 
decrease adherence of monocytes, we evaluated the adherence of human the monocytic cell lines 
U-937 to HAEC exposed to high glucose, in presence or absence of C-peptide.  
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Figure 4. C-peptide decreases high glucose-stimulated VCAM-1 mRNA after 4h and 24h.  
In (a) a representative example of RT-PCR detecting VCAM-1 mRNA expression in HAEC 
treated for 4h. b RT-PCR was used to detect VCAM-1 mRNA in HAEC treated with: low 
glucose (5.6 mmol/l; LG); high glucose (25 mmol/l; HG); HG+ 0.5 nmol/l C-peptide (C-P); HG 
+ 1 nmol/l C-P; HG+ 1 nmol/l heat-inactivated C-P (HI); LG + 10 ng/ml TNF-". GAPDH, 18S 
rRNA and #-actin were used as internal controls. c Densitometric analysis of VCAM-1 mRNA 
expression. Boxplot graphs showing the median values (limits of the lines are the 5th and 95th 
centiles of arbitrary units [AU]). C-peptide decreased high glucose-induced VCAM mRNA 
expression compared to high glucose alone. *p<0.05, ‡p= 0.008 vs 5.6 mmol/l. 
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Figure 5. C-peptide reduces high glucose-stimulated VCAM-1 protein expression on HAEC. Boxplot graphs 
showing the median values (limits of the lines are the 5th and 95th centiles) of MFI of VCAM-1expression in HAEC 
exposed to (a) 25 mmol/l glucose or (b) 5.6 mmol/l glucose with and without C-peptide (C-P) for 4 h as determined 
by flow cytometry (n=3 independent experiments). (a) HAEC exposed to 25 mmol/l glucose significantly increased 
VCAM-1 expression; †p=0.03 vs 5.6 mmol/l. This increase was significantly inhibited by 0.5 nmol/l C-peptide; 
**p<0.01. No significant changes in VCAM-1 were observed when C-peptide was added to basal medium 
containing 5.6 mmol/l glucose (b). HI, heat-inactivated 
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Figure 6. C-peptide reduces adhesion of U-937 to HAEC in condition of hyperglycaemia. HAEC were cultured 
in 25 mmol/l glucose in thpresence or absence of 0.5 nmol/l of C-peptide (C-P) for 4 h. U-937 were added for 1 h 
and then counted. a Boxplot graphs showing the median values of number of adherent U-937 per well ( n=3 sets of 
independent experiment). High glucose increased the number of adherent U-937; **p<0.01 vs. 25 mmol/l glucose 
alone. Heat-inactivated (HI) C-peptide (0.5 nmol/l) did not significantly alter adherence of U-937. TNF-" (10 
ng/ml) produced more than a fivefold increase in adherent U-937 in comparison to normal glucose. b Photographic 
view of U-937 adherent to HAEC. 
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Figure 7. C-peptide decreases high glucose stimulated MCP-1 and IL-8 secretion by HAEC. HAEC were 
cultured with high glucose (25 mmol/L) alone or combined to C-peptide (0.5 nmol/L) for 4 hours and secretion of 
MCP-1 and IL-8 in the supernatant assessed by ELISA. (a) Boxplot graphs showing the median values of secreted 
MCP-1 or IL-8 (on the Y axis) in the supernatant of HAEC exposed to 25mmol/L glucose compared to 5.6 mmol/L 
glucose (p=0.04). (b) Levels of IL-8 in supernatant of C-peptide-treated HAEC. HAEC treated with 25 mmol/L 
glucose in the presence of C-peptide showed a significant decrease in the levels of IL-8 in the supernatant, 
approaching levels measured in 5.6 mmol/L glucose (p< 0.05 vs. 25 mmol/L). A significant decrease in secreted 
MCP-1 and IL-8 was also found in HAEC treated with the NF-kB inhibitor PDTC (10%M). On the Y axis, MCP-1 
and IL-8 levels expressed as percent versus the appropriate control at 25 mmol/L. Shown are the average ± SD of a 
set of three independent experiments run in triplicate. 
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Figure 8. Expression of p65/p50 subunits of NF-kB in HAEC cultured in high glucose for 24 hours in the 
presence of C-peptide. HAEC were cultured in low glucose (LG; 5.6mmol/L) or high glucose (HG; 25 mmol/L) in 
the presence or absence of 0.5 nmol/L C-peptide for 24 hours. Cellular nuclear extracts were subjected to: a Western 
blotting to detect the 65-kDa band of the p65 subunit using a specific antibody (1:1,000); b Bar graph showing the 
densitometric quantitation of the bands. In cells exposed to HG there was a two-fold increase in NF-kB p65 nuclear 
translocation compared to cells in LG (p = 0.03). A decrease in NF-kB p65 nuclear translocation is observed when 
HAEC are exposed to HG + 0.5 nmol/L C-peptide (p< 0.05). Results are means ±SD (n = 3). Heat-inactivated (HI) 
C-peptide (0.5 nmol/L) was used as control; c Detection of the NF-kB p50 binding activity by using a EZ-DetectTM 
Transcription Factor kit (Pierce Biotechnolgy). Results were expressed as fold induction of NF-kB p50 activity in 
respect to control at 5.6mmol/L. In cells exposed to HG there was a two-fold increase in NF-kB p50 nuclear 
translocation compared to cells in LG (p = 0.002). A decrease in NF-kB p50 nuclear translocation is observed when 
HAEC are exposed to HG + 0.5 nmol/L C-peptide (C-P) (p < 0.01). Results are expressed as means ± SD (n= 3). 
Heat-inactivated C-peptide (HI C-P) was used as control of C-peptide activity.  
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We observed a threefold increase in the number of adherent U-937 under high glucose as 
compared to 5.6 mmol/L glucose. When C-peptide was added to the high glucose medium, the 
number of adherent U-937 cells was reduced (Figure 6a). 
Addition of heat inactivated C-peptide did not alter significantly the number of adherent 
cells as compared with 25mmol/L glucose alone. The adhesion of U-937 to HAEC exposed to 
different conditions was also photographed (Figure 6b). As expected, TNF-", which activates 
endothelial cells, produced a fivefold increase in U-937 adherence to HAEC compared to high 
glucose alone. Moreover, we found that C-peptide was able to decrease the secretion of the 
inflammatory cytokines IL-8 and MCP-1 from high glucose-exposed HAEC (Figure 7a-7b), 
which are important mediators in the process of monocyte adherence during endothelial 
dysfunction eventually leading to plaque formation. 
These effects were mediated by a reduced activation of NF-kB pathway by C-peptide 
(Figure 8), a pathway involved in inflammatory responses by decreasing its translocation into the 
nucleus. In the unstimulated state, infact, NF-!B exists in its canonical form as a heterodimer 
composed of p50 and p65 subunits bound to I!B in the cytoplasm. Upon activation, I!B is 
phosphorylated and degraded causing the release of p50/p65 components of NF-!B. The active 
p50/p65 heterodimer translocates to the nucleus and initiates the transcription of a gamut of 
genes involved in the inflammatory response, such as pro-inflammatory cytokines, cell surface 
adhesion molecules, and chemokines, including IL-8 and MCP-1  
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5.1 ABSTRACT 
Aim: Excessive proliferation of vascular smooth muscle cells (VSMCs) is one of the primary 
lesions in atherosclerosis development during diabetes. High glucose triggers VSMC 
proliferation and initiates activation of the transcription factor nuclear factor (NF)-!B. Recently, 
clinical studies have demonstrated that replacement therapy with C-peptide, a cleavage product 
of insulin, to Type 1 diabetic (T1D) patients is beneficial on a variety of diabetes-associated 
vascular complications. However, the mechanisms underlying the beneficial activity of C-
peptide on the vasculature in conditions of hyperglycemia are largely unknown. 
Material/Methods:The effects of C-peptide on the proliferation of human Umbilical Artery 
Smooth Muscle Cell (UASMC) and Aortic Smooth Muscle Cell (AoSMC) lines cultured under 
high glucose for 48 hours were tested. To gain insights on potential intracellular signaling 
pathways affected by C-peptide, we analyzed NF-!B activation in VSMCs since this pathway 
represents a key mechanism for the accelerated vascular disease observed in diabetes.Results: 
High glucose conditions (25mmol/L) stimulated NF-!B-dependent VSMC proliferation since the 
addition of two NF-!B-specific inhibitors, BAY-117082 and PDTC, prevented proliferation. C-
peptide at the physiological concentrations of 0.5 and 1nmol/L decreased high glucose-induced 
proliferation of VSMCs that was accompanied by decreased phosphorylation of I!B and reduced 
NF-!B nuclear translocation. Conclusions: These results suggest that in conditions of 
hyperglycemia C-peptide reduces proliferation of VSMCs and NF-!B nuclear translocation. In 
patients with T1D, physiological C-peptide levels may exert beneficial effects on the vasculature 
that, under high glucose conditions, is subject to progressive dysfunction.  
5.2 INTRODUCTION 
Patients with type 1 diabetes (T1D) exhibit an increased susceptibility to develop a wide range of 
vascular complications, including microangiopathy and atherosclerosis, which account for the 
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majority of deaths and disability in diabetic patients9. Elevated blood glucose levels 
(hyperglycemia) are considered one of the major causes of vascular complications in T1D 
patients11. 
Together with endothelial dysfunction, the proliferation of vascular smooth muscle cells 
(VSMCs) is one of the characteristic features of human atherosclerosis111. Under high glucose 
conditions, human, porcine and rat VSMC proliferate and migrate from the media to the 
subendothelial space of the vessel wall where early atherosclerotic lesions are localized 111-112. 
  In VSMCs, high glucose initiates the activation of the transcription factor NF-!B102, 
which leads to the transactivation of a number of genes involved in VSMC proliferation.  Several 
studies have pointed to an involvement of the NF-!B pathway in the process of atherosclerosis 
by acting at different pathophysiological levels during plaque development. The activated p65 
subunit has been found in macrophages, endothelial cells, and VSMCs within human 
atherosclerotic lesions71. Other studies mostly point to a role of NF-!B in regulating apoptosis of 
VSMCs and fine-tuning of the inflammatory response present in the injured vessel wall112. 
Overall, these studies support the idea that NF-!B activation in VSMCs represent a key 
mechanism for the accelerated vascular disease observed in diabetes. Strategies targeting NF-!B 
pathway activation to inhibit VSMC proliferation for the prevention or the treatment of 
cardiovascular diseases are emerging112.  
Despite intensive insulin treatment and well-controlled glucose levels, vascular 
complications are still common among T1D patients127. As well as reduced endogenous insulin, 
the level of C-peptide is also decreased in the plasma of T1D patients. This peptide is cleaved 
from proinsulin and released from the pancreas into the circulation in equimolar amounts to 
insulin. C-peptide was initially believed to have no biological effects apart from its role in insulin 
biosynthesis. However, recent evidence suggests that C-peptide may have a physiological role on 
a variety of cell types including the vasculature6-7. Moreover, results from small clinical trials 
where C-peptide was administered to T1D patients, showed that C-peptide ameliorates renal 
dysfunction12, stimulates skeletal muscle microcirculation14, and improves functional and 
structural abnormalities in peripheral nerves13. It was then proposed that C-peptide may represent 
an important factor in reversing or preventing microvascular damage associated with diabetes. 
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Supporting this hypothesis, was evidence that T1D patients receiving whole pancreas or islet 
transplantation exhibited improvement in vascular disease in comparison to patients receiving 
daily insulin injections to control their hyperglycemia26,27, 29,30.  
Several studies have focused on the direct effects of C-peptide on the vasculature, often 
with contradicting results. For example, while there seems to be concordance on the 
vasodilatatory properties of C-peptide7, it is still controversial whether C-peptide exerts pro-
atherogenic effects on the vasculature or vice versa. Other observations point instead to a 
protective role of C-peptide on vascular dysfunction in diabetes. For example, Kobayashi et al.123 
demonstrated that 3 weeks exposure to C-peptide inhibited high glucose-induced 
hyperproliferation of rat VSMCs. Another group showed that rat C-peptide inhibits leukocyte-
microvascular endothelium interaction in vivo17. 
This study evaluated 1) the effects of short-term exposure of C-peptide on high glucose-
induced proliferation of human VSMCs in vitro, and 2) determined whether the NF-!B pathway 
is involved in the intracellular signaling events associated with C-peptide in VSMCs, since to 
date, no data identifies or excludes NF-!B signaling as a molecular event associated with C-
peptide effects on VSMCs under high glucose conditions. 
5.3 RESULTS 
Excessive proliferation of vascular smooth muscle cells (VSMCs) is one of the primary lesions 
in atherosclerosis development during diabetes. Together with endothelial dysfunction, the 
proliferation of VSMCs is one of the characteristic features of human atherosclerosis 
development.  
Proliferation was assessed using Bromodeoxyuridine (BrdU) (Figure 9) which is 
incorporated into the newly synthesized DNA of replicating cells (during the S phase of the cell 
cycle), substituting for thymidine during DNA replication. Exposure of UASMC to 25 mmol/L 
glucose for 48 h significantly increased BrdU incorporation compared with control cells exposed 
to 5.6 mmol/L glucose (p=0.002). Administration of C-peptide at a dose of 0.5 (p<0.01), and 1 
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nmol/L (p<0.01) for 48 h significantly suppressed high glucose-induced increase in BrdU 
incorporation in UASMC compared to untreated and scrambled C-peptide-treated cells (Figure 
9a) (110). These findings were observed, as well, in aortic smooth muscle cells (AoSMC) when 
cultured for 48 h with 25 mmol/L glucose in the presence of 0.5 nmol/L (p< 0.01) and 1 nmol/L 
(p< 0.01) C-peptide (Figure 9b). High glucose conditions stimulated NF-!B-dependent VSMC 
proliferation since the addition of two NF-!B speci(c inhibitors, BAY11-7082 and pyrrolidine 
dithiocarbamate (PDTC), prevented proliferation (Figure9a-9b).   
In contrast, when UASMCs were cultured with regular medium (containing 5.6mmol/L 
of glucose) in the presence of C-peptide we detected increased BrdU incorporation as compared 
to regular medium in the absence of C-peptide (p<0.05) (Figure 10a). No significant increase in 
BrdU incorporation was detected in AoSMC exposed to regular medium in the presence of C-
peptide (Figure 10b). 
As additional prove of proliferation, Ki67+ immunostaining was performed (Figure 11). 
Ki67+ is a nuclear marker of proliferation in living cells and tissues. A significant increase in 
Ki67+ cells was observed under high glucose conditions (p=0.01 vs. 5.6 mmol/L), while addition 
of C-peptide reduced Ki67+ cell number (19.8% ±2.88) in comparison to cells exposed to 25 
mmol/L glucose only (26.8% ±2.91) (p = 0.02) (Figure 11a-11b). The increase in Ki67+ cells 
from UASMC grown under high glucose conditions was mediated by NF-!B activation since 
treatment with PDTC (20 µM), an NF-!B inhibitor, reduced the number of Ki67+ cells to basal 
levels detected in normal glucose conditions (p<0.01). To determine if high glucose-induced 
proliferation of UASMC was associated with activation of the NF-!B signaling pathway, 
immunoblot analysis and NF-kB-specific ELISAs were performed with nuclear extracts from 
stimulated-UASMC. As shown in Fig. 12a, high glucose (25 mmol/L) induced an increase in 
NF-!B p65 nuclear translocation in comparison to normal glucose (5.6 mmol/L) stimulated 
UASMC. The addition of C-peptide to the high glucose cultures decreased NF-!B p65 nuclear 
translocation to normal glucose levels (Figure 12a), while the addition of scrambled C-peptide 
did not suppress NF-!B activity (Figure 12a). 
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Figure 9. C-peptide reduces high glucose-induced proliferation of VSMCs. VSMCs were incubated with 
25mmol/L glucose in the presence or in the absence of C-peptide (C-P) for 48 hours and assayed for proliferation. In 
(a) BrdU incorporation shows cellular proliferation in high glucose (p=0.002 vs. 5.6mmol/L). C-peptide reduced 
high glucose-induced UASMC proliferation (p<0.01), while addition of scrambled C-peptide (Scr C-P) did not have 
any significant effect. Addition of the NF-kB inhibitors PDTC (20mM) and BAY-11078 (1mM) also showed a 
decrease in proliferation (p<0.01 vs. 25mmol/L glucose). In (b) BrdU incorporation in AoSMC demonstrates that 
high glucose stimulated cellular proliferation (p=0.048 vs. 5.6mmol/L). C-peptide significantly reduced high 
glucose-induced UASMC proliferation (p<0.01 vs. 25mmol/L), while addition of scrambled C-peptide (Scr C-P) did 
not have any effect. Addition of PDTC (20mM) and BAY-11078 (1mM) also showed a decrease in proliferation 
(p<0.01 vs. 25mmol/L glucose). Values are mean±SD of 10 different experiments run in triplicate. 
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Figure 10. C-peptide stimulates proliferation of VSMCs under normal glucose. VSMCs were incubated with 
5.6 mmol/L in the presence or in the absence of C-peptide (C-P) for 48 h and assayed for proliferation. In (a), BrdU 
incorporation in UASMC shows increased proliferation in the presence of 1 nmol/L C-peptide (p < 0.05 vs. 5.6 
mmol/L glucose), while addition of scrambled C-peptide (Scr C-P) did not have any significant effect. In (b), BrdU 
incorporation in AoSMC shows no significant effect of C-peptide on cellular proliferation under normal glucose.  
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Figure 11. C-peptide reduces the number of Ki67+ cells. In (a) Images of Ki-67-immunostaining (in red) in 
UASMC exposed for 48 hours to the different conditions, as stated. DAPI stainining was used to stain the nuclei (in 
blue). C-peptide addition to the high glucose medium reduced Ki67+ cell number. In (b) quantitation of Ki67+ cells. 
Bar graph shows percent of Ki-67+ cells (mean±SD) compared to DAPI staining (blue) from five random fields of 
four independent experiments. Exposure of UAMSC to 25mmol/L glucose increased number of Ki-67+ cells 
compared to normal glucose (p=0.01), while addition of C-peptide significantly reduced the number of Ki-67+ 
proliferating cells (p<0.05 vs. 25mmol/L glucose). Addition of the NF-kB inhibitor PDTC to the high glucose 
medium also reduced the number of Ki-67+ cells (p<0.01 vs. 25mmol/L glucose). 
 
b 
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Figure 12. Expression of p65 and p50 subunits of NF-kB in UASMC cultured in high glucose in the presence 
of C-peptide. UASMC were cultured in 5.6mmol/L or 25mmol/L glucose in the presence or absence of C-peptide 
(C-P) for 48 hours. Cellular nuclear extracts were subjected to Western immunoblotting to detect p65 levels using a 
specific antibody (1:1,000). Scrambled C-peptide (Scr C-P) was used as control. In (a) Representative immunoblot 
depicting the 65-kDa band of the p65 subunit. To show equal loading of the gel, staining for b-actin is also shown. 
In (b) Bar graph showing the densitometric quantitation of the bands (n=4 different experiments). There is a 
significant increase in NF-kB p65 nuclear translocation in cells under 25mmol/L glucose (p=0.038 vs. 5.6mmol/L) 
that is reduced with addition of C-peptide (p<0.05). Results are means ±SD. In (c) NF-kB binding activity of the p50 
subunit was examined using a EZ-DetectTM Transcription Factor kit (Pierce Biotechnology). Results were expressed 
as fold induction of NF-kB p50 activity respect to control at 5.6mmol/L. High glucose increased NF-kB p50 
activation as compared to normal glucose (p=0.02). This activation is decreased by addition of C-peptide to the high 
glucose medium (p<0.05 vs. 25mmol/L glucose alone).  
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Densitometry of the NF-!B p65 immunoblot demonstrated that high glucose-stimulated NF-!B 
p65 nuclear translocation (p= 0.038 vs. normal glucose) and that the addition of C-peptide (1 
nmol/L) during high glucose exposure reduced NF-!B p65 nuclear translocation by 2-fold as 
compared to high glucose alone (p < 0.05) (Figure 12b).  
NF-!B activation was also assessed with a NF-!B p50-specific ELISA with nuclear 
extracts from glucose-stimulated UASMCs, as shown in Fig. 12c. High glucose-induced a 
significant increase in NF-!B p50 binding activity in contrast to normal glucose (p = 0.02) and 
was efficiently ablated by the addition of C-peptide (p < 0.05). Similar results were obtained 
with AoSMC (data not shown).  
Nuclear translocation of NF-!B p65 was also determined by immunofluorescence 
staining. UASMC cultured in 25 mmol/L glucose resulted in an increase in NF-!B p65 nuclear 
translocation as demonstrated by the intense green fluorescence localized in the cell nuclei 
(Figure 13) and also from superimposing photomicrographs of DAPI-stained nuclei (blue) 
(Figure 13b) with green fluorescence (Figure 13c). Cells in normal glucose (5.6 mmol/L) 
retained NF-!B p65 in the cytoplasm (green fluorescence) with very little staining observed in 
the nuclei (Figure 13a). The addition of C-peptide (0.5 nmol/L) to high glucose-treated cells 
prevented NF-!B. The mechanism underlying NF-!B nuclear translocationfrom the cytoplasm to 
the nucleus is based on the phosphorylation of I!B-". The effect of C-peptide on high glucose-
induced phosphorylation of I!B-" was therefore investigated by Western blotting on 
cytoplasmic extracts from UASMC (Figure 14). As expected, an increase in the level of 
phosphorylated I!B (p-I!B-") was observed in the cytoplasmic extracts after UASMC treatment 
(48 h) with 25mmol/L glucose as compared to UASMC cultured in low glucose (5.6mmol/L) 
(Figure 14). Addition of C-peptide to the high glucose medium caused a decrease in the level of 
I!B-" as compared to cells exposed to high glucose in the absence of C-peptide (Figure 14). 
These results suggest that in conditions of hyperglycemia C-peptide reduces proliferation of 
VSMCs and NF-!B nuclear translocation. 
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Figure 13. C-peptide treatment reduces high glucose-induced nuclear translocation of NF-kB p65 subunit in 
UASMC. UASMC were serum-starved for 24 hours and then treated for 48 hours with either normal glucose, or 
high glucose, or high glucose in the presence of 0.5nmol/L C-peptide. Scrambled C-peptide (0.5nmol/L; Scr) was 
used as positive control. In (a) localization of NF-kB immunostaining using a monoclonal antibody against the p65 
subunit (green fluorescence); (b) UASMC nuclei stained with DAPI; (c) Composite images generated by 
superimposing photographs in A and B. As shown in (a), the green fluorescence corresponding to the p65 subunit 
was localized mostly in correspondence of the nuclei when cells were treated with 25mmol/L glucose. This was 
clearly shown by superimposing the DAPI nuclear staining in (b) with the green fluorescence. On the contrary, 
UASMC treated with C-peptide showed green fluorescence mostly localized in the cytoplasm, rather then in the cell 
nuclei. Three independent experiments were performed, and one representative photomicrograph sets (30x) is 
shown. 
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Figure 14. Inhibitory effect of C-peptide on phosphorylation of I!B-"  protein in UASMC. UAMSC were 
serum-starved for 24 h and then treated for 48 h with either 5.6 mmol/L glucose or 25 mmol/L glucose or 25 
mmol/L glucose + 0.5 nmol/L C-peptide (C-P) or 25 mmol/L glucose + 1nmol/L C-P. Cellular cytoplasmic extracts 
were subjected to Western immunoblotting to detect phosphorylated I!B-" (p-I!B-") using a specific antibody. In 
this figure, it is shown a representative immunoblotting depicting decreased phosphorylation of p-I!B-" with C-
peptide. Immunoblot for total I!B-" is also shown. Similar results were obtained in at least two independent 
experiments. 
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6.0  C-PEPTIDE REDUCES GLUCOSE INDUCED ROS PRODUCTION IN 
ENDOTHELIAL CELL BY AFFECTING THE NAD(P)H OXIDASE SUBUNIT RAC-1 
 
In this section, we investigated the effect of C-peptide to reduce cell death (apoptosis) and ROS 
generation in endothelial cells (HAEC) exposed to hyperglycaemia. We also investigated 
whether C-peptide affects the activity of the enzymatic complex called NAD(P)H oxidase, which 
is considered to be one of the major sources of ROS production in EC after exposure to 
hyperglycemia84.  
Exposure of HAEC to high glucose medium (25mmol/L) for 48 hours significantly 
increased DNA fragmentation as compared to cells in normal glucose (p<0.01), as shown in 
Figure 15a. Addition of C-peptide to the high glucose media significantly reduced HAEC 
apoptosis, as compared to high glucose alone (p<0.05). This corresponded to a 25% reduction of 
apoptosis by C-peptide as compared to high glucose (Figure 15b).  
One crucial mediator of apoptosis is the activated caspase-3 proteases, which catalyzes 
the specific cleavage of many key cellular proteins. We evaluated endogenous levels of the large 
fragment (17/19kD) of activated (cleaved) caspase-3 by Western blotting in cell lysates from 
HAEC exposed to high glucose overnight. As shown in Figure 16a, expression of cleaved 
caspase-3 was higher in cell lysates from HAEC under high glucose compared to normal glucose 
conditions (p<0.05). Addition of C-peptide reduced endogenous levels of activated caspase-3 in 
cell lysates of HAEC compared to high glucose alone (p<0.05), a result that was not observed 
with scrambled C-peptide (Figure 16a-16b).  
Caspase-3 activity in high glucose-exposed HAEC was also assessed in vitro on cell lysates by 
ELISA. As shown in Figure 16c, exposure to high glucose overnight significantly increased 
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caspase-3 activity compared to normal glucose (p<0.01). Addition of C-peptide to the high 
glucose medium, significantly reduced caspase-3 activity (p<0.01 vs. high glucose alone), while 
scrambled C-peptide was without significant effects (Figure 16c). Analysis of expression of the 
product of the survival gene Bcl-2 by Western blotting showed a decreased level of protein 
expression in cell lysates of HAEC exposed to high glucose overnight (Figure 17a) (p<0.05). 
Addition of C-peptide to the high glucose medium increased Bcl-2 protein expression as 
compared to high glucose alone (Figure 17a) (p<0.05). 
Intracellular ROS produced by HAEC was assessed using a fluorescent dye called 
carboxy-DCFDA, which is a cell-permeant indicator for ROS. Treatment with high glucose on 
HAEC was found to increase CM-H2-DCFDA fluorescence in a time-manner, as compared to 
normal glucose. Figure 18a shows that CM-H2-DCFDA fluorescence in HAEC exposed to high 
glucose increased progressively from time 0 to 5 hours after addition of the dye, as compared to 
control levels of glucose (p<0.05 vs. normal glucose at 3 hours). C-peptide addition to the high 
glucose medium completely significantly suppressed the increased in CM-H2-DCFDA 
fluorescence induced by high glucose at all time points and reaching statistical significance at 3 
hours (p<0.01 vs. high glucose) and 4 hours (p<0.01 versus high glucose) (Figure 18a). When 
scrambled C-peptide was added to high glucose, no significant decrease in CM-H2-DCFDA 
fluorescence was detected in HAEC as compared to high glucose alone (Figure 18a). Figure 18b 
shows representative histgrams of flow cytometry analysis of CM-H2-DCFDA fluorescence in 
HAEC under the different treatment conditions after 4 hour.  
We also tested the effect of C-peptide to decrease the level of oxidative stress in 
hyperglycaemia-induced HAEC generated by the activity of NAD(PH) oxidate. Percent of 
NAD(P)H oxidase activity in HAEC upon different treatment conditions (30 min) are shown in 
Figure 18c.  NAD(P)H oxidase activity decreased in presence of C-peptide (<60% less; p<0.01 
vs. HG) compared to high glucose alone. Pre-incubation of HAEC with NAD(P)H oxidase 
inhibitors Apocynin (10mmol/L) and DPI (100mmon/L) for 2 hours, drastically reduced 
NAD(P)H oxidase activity in HAEC successively exposed to high glucose for 30 minutes. We 
then decided to focus our investigation on Rac-1, a small GTPase, which is a cytosolic subunit 
that upon stimulation translocates to plasma membrane in order to form the NAD(P)H oxidase 
enzymatic complex together with other subunits.  
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To determine if high glucose-induced translocation of Rac-1 from cytoplasm to plasma 
membrane was affected by C-peptide, we performed immunoblot analysis on plasma membrane 
and cytosolic proteins from stimulated-HAEC. 
We showed that high glucose induced the translocation of Rac-1 subunit from the 
cytoplasm to the plasma membrane (Figure 19a-b) (p< 0.05 compared to NG) after 30 minutes 
treatment. Addition of C-peptide to HAEC previously exposed to high glucose, led to a 
decreased localization of Rac-1 on the membrane and higher presence of Rac-1 in the cytoplasm 
(p<0.05 vs high glucose condition) while scrambled C-peptide was without significant effects 
(Figure 19a-b). We tested whether C-peptide treatment for 30 min had any effects on mRNA 
gene expression of Rac-1 in high glucose-exposed HAEC. As shown in Figure 6C, we did not 
find any significant differences in mRNA expression for Rac-1 in HAEC exposed to C-peptide 
as compared to high glucose alone (Figure 19c).  
The activity of Rac-1 using 10 µg of cell lysates was evaluated by G-LISATM assay. We 
observed that after serum starvation, high glucose increased Rac GTPase activity in HAEC after 
30 minutes treatment compared to normal glucose condition (Figure 20) (p<0.01). Addition of C-
peptide to HAEC exposed to high glucose, reversed the activation of Rac GTPase activity to 
basal level (p<0.01 vs high glucose) while scrambled C-peptide was without significant effects 
(Figure 20). As further control of high glucose-induced Rac-1 translocation and activity, these 
experiments were performed using cell culture medium that lacked hEGF, known as Rac 
activator, during both serum starvation and treatments 
 
 
 
 
 
 
 
 
 
 
  58 
6.1 FIGURES OF CHAPTER 6.0 
 
 
Figure 15. C-peptide decreases generation of histone-associated-DNA fragments in HAEC exposed to high 
glucose for 48 h. HAEC were seeded in 96 well-plate and exposed to either normal glucose, or high glucose (25 
mmol/L) or high glucose + C-peptide (10 nmol/L) or high glucose + Scrambled C-peptide for 48 h. Changes of 
cytoplasmic histone-associated-DNA fragments upon different treatment conditions were detected using DNA 
fragmentation ELISA. In (a), significant increase of DNA fragments in HAEC exposed to high glucose for 48h 
compared to normal glucose  (p<0.01 vs. 5.6 mmol/L glucose). DNA fragments decreased in the presence of 10 
nmol/L C-peptide (p < 0.01 vs. 25 mmol/L glucose), while addition of scrambled C-peptide (Scr. CP) did not have 
any significant effect. In (b), percent of DNA fragmentation in HAEC exposed to high glucose + C-peptide 
compared to high glucose alone (25 % less). Values are mean ± S.D. of three different experiments run in triplicate. 
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Figure 16. C-peptide decreases caspase-3 activity and expression in HAEC exposed to high glucose. HAEC 
were cultured in normal glucose (NG; 5.6mmol/L) or high glucose (HG; 25 mmol/L) in the presence or absence of 
10 nmol/L C-peptide overnight. Cellular cytoplasmic extracts were subjected to Western blotting (a) to detect the 
19-kDa band of the cleaved caspase-3. In (b) bar graph showing the densitometric quantitation of the bands. In cells 
exposed to HG there was a two-fold increase in cleaved caspase-3 compared to cells in NG (p < 0.05). A decrease in 
cleaved caspase-3 is observed when HAEC are exposed to HG + 10 nmol/L C-peptide (p< 0.05). Results are means 
±SD (n = 3). Scrambled (Scr. Cp) C-peptide (10 nmol/L) was used as control; c Detection of the caspase 3activity 
by using a kit (Calbiochem). Results were expressed as fold induction of caspase-3 activity in respect to control at 
5.6mmol/L. In cells exposed to HG there was a 1.5-fold increase in caspase-3 activity compared to cells in NG (p < 
 
 
 
         a)  
 
         b) 
 
 
 
 
 
 
 
 
 
 
      c) 
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0.01). A decrease in caspase-3 activity is observed when HAEC are exposed to HG + 10 nmol/L C-peptide (p < 
0.01). Results are expressed as means ± SD (n= 3). Scrambled C-peptide (Scr. CP; 10 nmol/L) was used as control. 
 
 
 
 
Figure 17. C-peptide increases Bcl-2 expression in HAEC exposed to high glucose. In (a) a typical western blot 
of Bcl-2 and #–actin in endothelial cells treated in high glucose overnight. In (b) Bar graph showing the 
densitometric quantitation of the bands. Bcl-2 expression was significantly decrease in condition of high glucose (p< 
0.05 compared to NG)., On the other hand, addition of C-peptide to HAEC previously exposed to high glucose, led 
to an increased expression of Bcl-2 suggesting an activation of the cell survival pathway (p<0.05). 
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Figure 18. Measurements of oxidative stress in HAEC exposed to high level of glucose. In (a) detection of ROS 
accumulation in culture HAEC was performed using a carboxy-dichlorodi-hydrofluorescein diacetate (carboxy-H2-
DCFDA). Briefly, HAEC were treated with the indicated treatment overnight and the following day, incubated with 
the carboxy-H2-DCFDA dye (10µmol/L) for 30min. After incubation time, HAEC were immediately read at the 
flow cytometer (time 0). HAEC were then maintained at 37°C and intracellular ROS production monitored every 
hour until 5 hours. As shown in (a) high glucose was able to increase the production of ROS vs. normal glucose 
condition in HAEC (paired t-test: 3h p=0.01; 4h p<0.01). C-peptide treatment showed to decrease ROS production 
in HAEC exposed to high glucose overnight. In (b), a representative fluorescence emission graph of oxidized dye for 
ROS detection. In (c) percent of NAD(P)H oxidase activity in HAEC upon different treatment conditions (30 min).  
NAD(P)H oxidase activity decreased in presence of C-peptide (<60% less; p<0.01 vs. HG) compared to high 
glucose alone. Inhibitors Apocynin (10µM) and DPI 100µM) drastically reduced NAD(P)H oxidase activity in 
HAEC exposed to high glucose. Scrambled C-peptide was used a control. 
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Figure 19. Effect of C-peptide on Rac-1 translocation in HAEC exposed to high glucose. In (a) western blot of 
cytoplasmic (Rac-1-c) and membrane (Rac-1-m) Rac-1 expression in endothelial cells treated in high glucose, in 
presence or absence of C-peptide (10 nmol/L) for 30 minutes. In (b) Bar graph showing the densitometric 
c  
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quantitation of the bands. High glucose condition induced the translocation of Rac-1 subunit from the cytoplasm to 
the plasma membrane (p< 0.05 compared to NG). Addition of C-peptide to HAEC previously exposed to high 
glucose, led to a decreased localization of Rac-1 on the membrane and higher presence of Rac-1 in the cytoplasm 
(p<0.05 vs high glucose condition). In c) effect of treatment condition on Rac-1 mRNA in HAEC 
 
 
 
 
 
 
Figure 20. C-peptide decreases Rac GTPase activation in HAEC exposed to hyperglycaemia after 30 minutes. 
HAEC were serum starved overnight and exposed to regular EBM-2 media containing either normal glucose, or 
high glucose, or high glucose+ C-peptide (10 nmmol/L) or scrambled C-peptide (10nmol/L) for 30 minutes at 37°C. 
EGF, known as Rac activator, was removed from the EBM-2 media during both serum starvation and treatments. 10 
µg of cell lysates were then subjected to the G-LISATM assay and absorbance was read at 490 nm. High glucose 
condition increased Rac GTPase activity in HAEC after 30 min of treatment compared to normal glucose condition 
(p<0.01). Addition of C-peptide to HAEC exposed to high glucose, reversed the activation of Rac GTPase activity 
to basal level (p<0.01 vs high glucose). 
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7.0  C-PEPTIDE REDUCES PRO-INFLAMMATORY CYTOKINE SECRETION IN 
LPS-STIMULATED U937 MONOCYTES IN CONDITION OF HYPERGLYCEMIA 
 
We investigated the effect of C-peptide on pro-inflammatory cytokine secretion by LPS-treated 
U-937 monocytes. As expected, exposure of U-937 cells to high glucose and LPS for 24 hours 
significantly stimulated secretion of several pro-inflammatory cytokines, such as IL-6, IL-8, 
macrophage inflammatory protein (MIP)-1", and MIP-1# (Figure 22a-d). Addition of C-peptide 
(1µmol/L) to the LPS-treated U-937 monocytes statistically significantly reduced secretion of 
IL-6, IL-8, MIP-1" and MIP-1# (Fig. 21a-d). Addition of scrambled C-peptide (1µmol/L) to the 
culture medium did not significantly affect LPS-induced cytokine secretion after 24 hours 
incubation (Figure 21a-d). 
We then assessed adherence of U-937 monocytes to HAEC after exposure of monocytes 
to C-peptide and glucose at various concentrations. When C-peptide was added to 30mmol/L 
glucose, there was a significantly decreased number of adherent monocytes as compared to high 
glucose alone (p<0.05), (Figure 22a). As a positive control, IL-1# was used to stimulate 
adherence of U-937 monocytes to HAEC (p<0.01 vs. high glucose). In low and intermediate 
glucose conditions, C-peptide did not show significant effects on U-937 monocyte adherence. In 
Figure 22b, are shown images of U-937 monocyte adhesion under the different conditions tested.  
The signal transduction pathway leading to mRNA synthesis of adhesion molecules and 
chemokines involves activation of NF-!B. To determine whether C-peptide affected high 
glucose-induced NF-!B nuclear translocation in LPS-stimulated U937 monocytes, immunoblot 
analysis and NF-!B-specific ELISAs were performed with nuclear extracts from LPS-stimulated 
U-937. As shown in Figure 23a, exposure of U-937 to LPS for 24 hours induced an increase in 
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NF-!B nuclear translocation in comparison to cells without LPS stimulation. A two-fold increase 
in NF-!B p65 activation was found after 24 hours stimulation with LPS as compared to 
incubation with 30mmol/L glucose alone (p<0.05) (Figure 23a-b). Addition of C-peptide 
significantly decreased NF-!B p65 nuclear translocation (Figure 23a).  Densitometric analysis of 
this NF-!B p65 immunoblot demonstrated that C-peptide (1µmol/L) reduced NF-!B p65 nuclear 
translocation as compared to stimulation with LPS (p < 0.05) (Figure 23b). Addition of C-
peptide to LPS-treated U937 monocytes also reduced NF-!B p50 subunit nuclear translocation 
as compared to LPS-treatment alone, as detected by ELISA (p=0.0042) (Figure 23c).  
The mechanism underlying NF-!B nuclear translocation from the cytoplasm to the 
nucleus is based on the phosphorylation of I!B-". We therefore investigated the effects of C-
peptide on LPS-induced phosphorylation of I!B-"  by Western blotting on cytoplasmic extracts 
from U-937 cells (Figure 24). As expected, an increase in the level of phosphorylated I!B-" (p-
I!B-") was observed in the cytoplasmic extracts of LPS-stimulated U937 monocytes after 24 
hours treatment compared to U937 cells cultured in 30mmol/L glucose alone (Figure 24). 
Addition of C-peptide caused a decrease in the level of p-I!B-" as compared to cells exposed to 
LPS in the absence of C-peptide (Figure 24). 
 
 
 
 
 
 
 
 
 
 
 
 
 
  67 
7.1 FIGURES OF CHAPTER 7.0 
 
 
 
Figure 21. C-peptide reduces LPS-stimulated secretion of IL-6, IL-8, MIP-1a, and MIP-1b in U937 
monocytes. U-937 cells were cultured with 30mmol/L glucose and stimulated with 0.5 ng/mL of 
Lipopolysaccharide in the presence or absence of 1µmol/L C-peptide for 24 hours.  Scrambled C-peptide (1µmol/L) 
was used as a control. Luminex multiplex assays were used to assess levels of IL-6, IL-8, MIP-1a and MIP-1b in the 
culture supernatants of LPS-stimulated U937 cells. Bar graphs demonstrate cytokine secretion (pg/mL). Cells 
exposed to LPS produced more cytokines than cells exposed to high glucose alone (p<0.001). Addition of C-peptide 
to the LPS-treated U-937 monocytes reduced secretion of IL-6, IL-8, MIP-1a and MIP-1b (p<0.05, p=0.0005, 
p=0.0001, p=0.0001, respectively). Addition of scrambled C-peptide to the culture medium did not significantly 
affect LPS-induced cytokine secretion. A minimum of 4 independent experiments was performed. Each condition 
was tested in duplicate. Results are expressed as mean ± SD. 
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Figure 22. C-peptide reduces adhesion of U937 monocytes to HAEC. U-937 monocytes were cultured in either 
low (5.6mmol/L), intermediate (11mmol/L), or high glucose (30mmol/L) medium, in the presence or absence of C-
peptide for 4 hours. Subsequently, the U937 were added to confluent HAEC and allowed to incubate for 1 hour and 
then counted. (A) Bar graphs demonstrating the number of adherent U937 per well (n=at least 3 sets of independent 
experiments with each condition tested in triplicate). Intermediate and high glucose increased the number of 
adherent U937 compared to low glucose. The addition of C-peptide to U937 cultured in low- or intermediate-
glucose did not demonstrate a significant affect on adhesion. When C-peptide was added to high glucose, there was 
a decreased number of adherent monocytes as compared to high glucose alone (p<0.05). As a positive control, IL-1# 
was used to stimulate adherence of U-937 monocytes to HAEC (p<0.01 vs. high glucose). Results are expressed as 
mean ± SD. (B) Photographic images of U-937 monocyte adhesion under the various conditions tested.  
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Figure 23. C-peptides diminishes nuclear translocation of p65/p50 subunits of NF-kB in LPS-stimulated 
U937. U-937 cells were cultured in complete RPMI-1640 with 30 mmol/L glucose and exposed to LPS (0.5ng/µL) 
in the presence or absence of C-peptide for 24 hours. (a) Nuclear extracts were subjected to western blotting to 
detect p65 subunits of NF-kB. (b) Densitometric quantification of the band at 24 h. In cells exposed to LPS there 
was a two-fold increase in NF-!B p65 nuclear translocation compared with cells in HG alone (p<0.05). A decrease 
in p65 nuclear translocation was observed in the presence of 1 µmol/L C-P: p<0.05 vs LPS. Results are expressed as 
means±SD (n=3). (c) Detection of the NF-kB p50 binding activity by ELISA after 24 h. Results are expressed as 
fold induction of NF-kB p50 activity in respect to 30 mmol/L glucose. In cells exposed to LPS there was a 1.5 
increase in NF-!B p50 nuclear translocation compared to cells in HG alone. A decrease in NF-!B p50 nuclear 
translocation was observed in the presence of 1 µmol/L C-peptide (C-P); p=0.0042 vs LPS condition. 
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Figure 24. Inhibitory effect of C-peptide on phosphorylation of IkBa protein in LPS-stimulated U937 
monocytes. Cytoplasmic extracts (50 µg) were incubated overnight at 4ºC with anti-I!B" IgG (1:100). The samples 
were then treated with 10 µl of protein A agarose beads for 2 h at 4ºC after which the samples were centrifuged and 
washed in PBS. The beads were boiled in SDS-PAGE sample treatment buffer and electrophoresed on a 4-20% 
SDS-PAG. The gel was blotted and incubated with either monoclonal P-I!B" or I!B" antibodies (both from Santa 
Cruz Biotechnology; 1:1000). (Upper panel) An increase in the level of phosphorylated-IkB-a (p-IkBa) was 
observed in the cytoplasmic extracts of LPS-stimulated U937 monocytes after 24 hours treatment compared to U937 
cells cultured in 30mmol/L glucose alone. Addition of 1mmol/L C-peptide caused a decrease in the level of p-IkBa 
as compared to cells exposed to LPS in the absence of C-peptide. (Lower panel) Total IkB-a  levels did not change 
upon treatment conditions.  
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8.1 ABSTRACT  
Aims: There is increasing evidence that C-peptide exerts intracellular effects in a variety of cells 
and could be beneficial in patients with type 1 diabetes. How exactly C-peptide achieves these 
effects, however, is still unknown. Recent reports showed that C-peptide internalizes in the 
cytoplasm of HEK-293 and Swiss 3T3 cells, where it is not degraded for at least 1 hour from 
uptake. In this study, we investigated the hypothesis that C-peptide is internalized via an 
endocytic pathway and traffics to classic endocytic organelles, such as endosomes and 
lysosomes. Methods: We studied internalization of C-peptide in vascular endothelial and smooth 
muscle cells, two relevant targets of C-peptide activity, by using AlexaFluor-labelled C-peptide 
probes in live-cells and immunohistochemistry employing confocal laser-scanning microscopy. 
To examine trafficking to sub-cellular compartments, we used fluorescent constructs tagged to 
Rab5a to identify early endosomes, or to Lamp1 to identify lysosomes. Results: C-peptide 
internalizes in the cytoplasm of cells within punctate structures identified as early endosomes. 
Internalization was clearly detectable after 10 min of incubation and was blocked at 4ºC as well 
as with excess of unlabelled C-peptide. A minority fraction of vesicles, which increased with 
culture time, co-localized with lysosomes. Uptake of C-peptide was reduced by 
Monodansylcadaverine (MDC), a pharmacological compound that blocks clathrin-mediated 
endocytosis, and by Nocodazole, which disrupts microtubule assembly. Conclusions: C-peptide 
internalizes in the cytoplasm of cells via endocytosis as demonstrated by localization in early 
endosomes. Endosomes might represent a signaling station, through which C-peptide might 
achieve its cellular effects. 
 
8.2 INRODUCTION 
 
Human C-peptide is a 31 amino acid long peptide released by pancreatic beta cells in 
equimolar amounts with insulin in response to elevated blood glucose levels (hyperglycaemia). 
Once secreted in the bloodstream, C-peptide circulates at low nanomolar concentrations in 
healthy individuals, but it is absent in the majority of type 1 diabetes patients2. In recent years, C-
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peptide has been shown to exert insulin-independent biological effects on a variety of cells, 
where it affects activation of several intracellular pathways, such as, but not limited to, those 
involved in cellular proliferation and inflammation6-8. Importantly, C-peptide has been 
demonstrated to be beneficial when administered as replacement therapy to type 1 diabetes 
patients who suffer from some diabetic complications12-15. How exactly C-peptide achieves its 
intracellular effects in target cells, however, is still unknown.  
Several years ago, C-peptide was shown to specifically bind to plasma membranes from 
rat pancreatic beta cells149, human renal tubular cells150, human fibroblasts and endothelial 
cells106. More recently, C-peptide was shown to bind and cross plasma membranes localizing in 
the cytoplasm of HEK-293 cells and Swiss 3T3 fibroblasts115, where it was detected up to 1 h 
after its uptake. A nuclear localization of C-peptide in HEK-293 cells and Swiss 3T3 fibroblasts 
has also been demonstrated by the same group115. These findings demonstrate that once 
internalized in the cytoplasm, C-peptide is not rapidly degraded but remains intact, possibly 
interacting with sub-cellular components through which it might achieve its cellular effects.  
The process of internalization from the cell surface and sub-cellular localization of C-
peptide in target cells have not yet been investigated. In particular, it is not known whether C-
peptide passively diffuses across the cellular membrane or whether it is actively translocated by a 
specific pathway of internalization, such as endocytosis. In this study, we investigated the 
hypothesis that C-peptide internalizes in target cells by following a specific endocytic pathway.  
C-peptide internalization was explored in HAEC and UASMC, two important targets of 
C-peptide activity especially in the context of vascular dysfunction leading to vascular 
complications in type 1 diabetes107,110. We found that in these cells C-peptide internalizes from 
the cellular surface within punctate structures, a majority of them co-localizing with early 
endosomes. A minority fraction of C-peptide vesicles, which increases with culture time, is 
localized within the lysosomes for degradation. These results demonstrate that C- peptide 
internalizes in target cells by using a specific endocytic pathway. Endosome localization of C-
peptide would support the proposal that C-peptide might achieve its cellular effects in part by 
signaling from these organelles.  
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8.3 RESULTS 
 
C-peptide internalization was explored in human endothelial and smooth muscle cells by using 
fluorescently-labeled C-peptide125. In these cells, C-peptide internalizes to punctate structures 
localized at the level of the cellular membrane and in the cytoplasm (Figure 25). Internalization 
of C-peptide was minimal after 5minutes, clearly detectable after 10 minutes, resulted in bright 
staining after 30 minutes, and internalization was completed by 1 hour.   
Consistent with the cellular trafficking of proteins in general, the internalization of C-
peptide was blocked at 4ºC. (Figure 26a). Accordingly, C-peptide internalization slowly 
recovered when cells that were incubated at 4ºC were placed back at 37ºC (Figure 26b-c). 
As shown in Figure 27b, pre-incubation of HAEC with 30-fold excess of unlabelled C-
peptide blocked uptake of the fluorescent C-peptide probe as compared to cells incubated with 
AlexaFluor488-labelled C-peptide only (Figure 27a). On the contrary, pre-incubation of HAEC 
with a scrambled version of unlabelled C-peptide did not interfere with AlexaFluor488-labelled 
C-peptide internalization (Figure 27d). 
C-peptide uses a clathrin-mediated endocytotic pathway to enter HAEC. Pre-treatment of 
HAEC with MDC (43µmol/L) for 30 min completely blocked uptake of AlexaFluor488-labelled 
C-peptide (p<0.01 versus control) (Figure 28). By contrast, Filipin pre-treatment of HAEC for 30 
min (5µg/mL) lacked nearly completely inhibitory effect on fluorescent C-peptide probe 
internalization (Figure 28e). MDC is a pharmacological inhibitor of receptor-mediated 
endocytosis,117,118 while Filipin, which binds cholesterol in the plasma membrane, impairs the 
invagination and subsequent internalization of caveolae.122,123  
 The involvement of the cytoskeleton network in C-peptide endocytosis was studied in 
HAEC with Cytochalasin D (30µmol/L) and Nocodazole (10µmol/L), which act by inducing 
depolymerization of actin filaments and microtubules, respectively.25,126 As shown in Figure 28, 
uptake of AlexaFluor488-labelled C-peptide following Cytochalasin D treatment was not 
significantly different from control cells. Conversely, Nocodazole drastically reduced fluorescent 
C-peptide uptake (p<0.01 versus control) suggesting that entry of C-peptide into HAEC was 
dependent on microtubule integrity. 
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To explore the possibility that C-peptide localizes in early endosomes, HAEC and 
UASMC were transduced with Organelle LightsTM Endosome-GFP reagent, which targets 
expression of fluorescent Rab5a, an early endosome-specific marker. Live-cells were then 
labelled with 1 µmol/l AlexaFluor546-labelled C-peptide and imaged under a confocal 
microscope. As shown in Figure 29a, early endosomes appear as green punctate structures in the 
cytoplasm and close to the cellular membrane of an endothelial cell. Figure 29b shows 
internalization of AlexaFluor546-labelled C-peptide as red punctate staining inside the cytosol. 
When the two images were merged, a yellow staining is evident, corresponding to co-
localization of the green, early endosomes, with the red, C-peptide (Figure 29c, see arrows). In 
the majority of cases the red staining corresponding to the internalized C-peptide probe is 
evidently contained inside the endosome structures, observed as a bright yellow peripheral 
staining around the central red staining of the vesicles (Figure 29c-d). 
 As an additional technique to demonstrate co-localization of C-peptide to endocytic 
organelles, we performed immunofluorescence studies on PFA-fixed HAEC after exposure to 10 
nmol/L of C-peptide. As shown in Figure 30a, C-peptide internalizes in HAEC as green punctate 
structures, the majority of which localize with the red early endosomes (Figure 30b) identified 
with a monoclonal antibody to the early endosome antigen 1 (EEA1), resulting in a yellow 
staining (Figure 30c). 
To isolate early endosomes, we briefly incubated UASMC with AlexaFluor546-labelled 
C-peptide together with AlexaFluor488-conjugated human transferrin, and then proceeded to 
cellular fractionation. High-speed centrifugation allows plasma membranes and other cellular 
compartments to sediment in the pellet, while clathrin-coated pits and early endosomes, which 
are relatively small molecules120 (100-200nm), remain in the supernatant. By using a scanning 
fluorimeter, we quantified the fluorescence present in the endosome-containing supernatant of 
the homogenized cells. As shown in Figure 31, the mean fraction of the AlexaFluor488-
transferrin fluorescence (peak emission at 516), in the endosome-containing supernatant was 
0.86 + 0.06 (n = 3). The mean fraction of AlexaFluor546-C-peptide (peak emission at 568), in 
the endosome-containing supernatant was 0.77 + 0.08 (n = 3). The fraction of each probe in the 
supernatant versus pellet was significantly different (p<0.001), whereas the fraction of transferrin 
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and C-peptide in the endosomal fraction were statistically indistinguishable (p>0.05). The cell 
fractionation results further support the internalization of C peptide into early endosomes. 
 A final destination of internalized peptides along the endocytic pathway includes the lysosomes, 
where proteolytic degradation occurs. To visualize lysosomes, cells were transduced with 
Organelle LightsTM Lysosome-GFP reagent, which targets the lysosome-specific protein Lamp1, 
before labeling the cells with fluorescent C-peptide. By live-cell confocal microscopy, we found 
that a fraction of green AlexaFluor488-labelled C-peptide vesicles (Figure 32a) co-localized with 
the red lysosomes (Figure 32b), observed as yellow staining (Figure 32c). The fraction of C-
peptide co-localized with lysosomes increased with culture time. We did not find evidence of 
localization of fluorescent C-peptide in mitochondria of live HAEC and UASMC.  
 
 
 
 
 
 
 
 
 
 
 
Figure 25. C-peptide internalizes in HAEC and UASMC as punctate structures. HAEC  (a) and UASMC (b) 
were incubated for 30 min with 1 mmol/l AlexaFluor488-labelled C-peptide at 37ºC, washed with medium and 
imaged by using confocal microscopy. The green punctate-staining corresponds to the C-peptide probe localized at 
the periphery of the cell and in the cytoplasm. In (c) as a control for the specificity of the staining, HAEC were 
incubated for 30 min with 1 mmol/l AlexaFluor488 dye at 37ºC. Note the absence of green fluorescence staining. 
The Figure shows a representative z-section across one cell. 
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Figure 26. C-peptide internalisation is inhibited at 4°C. (a) HAEC were incubated for 30 min with 1 mmol/l 
Alexa Fluor 488-labelled Cpeptide at 4°C, washed, and immediately imaged by confocal microscopy. The figure 
shows absence of green fluorescence staining inside the cells, consistent with no internalisation of the probe. (b) 
Internalisation of green C-peptide probe slowly recovered when cells were put in the incubator at 37°C after being at 
4°C. Arrows show examples of green punctate staining corresponding to the internalised C-peptide probe. (c) 
Differential interference contrast confocal image of the same z-section as in b merged with the fluorescence image 
to demonstrate localisation of green punctate staining in the cytoplasm.  
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Figure 27. Alexa Fluor 488-labelled C-peptide internalisation is inhibited by an excess of unlabelled C-
peptide. (a) HAEC were incubated for 30 min with 1 mmol/l Alexa Fluor 488-labelled C-peptide at 37°C, washed 
with medium, and immediately imaged by confocal microscopy. The figure shows green punctate staining inside the 
periphery and cytoplasm of the cell, consistent with internalisation of the probe. (b) Internalisation of the Alexa 
Fluor 488-labelled green C-peptide probe (1 mmol/l) was inhibited by preincubation with 30 mmol/l unlabelled C-
peptide for 1 h at 37°C. (c) Differential interference contrast confocal image of the z-section shown in b. Arrows 
indicate examples of three different cells showing reduced green punctate staining in the cytoplasm. (d) 
Preincubation of cells with 30 mmol/l of a randomised version of C-peptide (scrambled C-peptide) did not affect 
internalisation of Alexa Fluor 488-labelled C-peptide, as demonstratedby the presence of green punctate staining 
inside the cytoplasm.  
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Figure 28. Effect of different pharmacological compounds on C-peptide entry into HAEC. Cells were either 
treated with 1 mmol/l Alexa Fluor488-labelled C-peptide for 30 min (control) or pretreated with the following 
compounds before addition of 1 mmol/l Alexa Fluor 488-labelled C-peptide: MDC (43 mmol/l), filipin (5 mg/ml), 
cytochalasin D (30 mmol/l) and nocodazole (10 mmol/l). As shown, pretreatment of HAEC with MDC, an inhibitor 
of clathrin-mediated endocytosis, inhibited entry of the C-peptide probe. Pretreatment with nocodazole, which 
prevents microtubule assembly, also impairs C-peptide internalisation. Filipin and cytochalasin D did not inhibit C-
peptide internalisation.a–e Representative z-section across some endothelial cells. (f) The mean fluorescence (AU, 
arbitrary units) of Alexa Fluor 488-conjugated C-peptide internalisation measured in each experimental condition. 
The asterisk indicates that a significant decrease in uptake of fluorescent C-peptide was detected when HAEC were 
pretreated with MDC and nocodazole (p<0.01 vs control cells) 
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Figure 29. Internalized AlexaFluor546-labelled C-peptide co-localizes with early endosomes in UASMC. 
UASMC were transduced with Organelle LightsTM Endosomes-GFP, which induces expression of the fluorescent 
early endosomal marker Rab5a, and then incubated for 30 min with 1 mmol/l AlexaFluor546-labelled C-peptide at 
37ºC. After washing the cells with fresh medium, cells were imaged by confocal microscopy. In (a) the yellow 
staining corresponds to the merging of the green fluorescence (early endosomes) with the red fluorescence (C-
peptide).  In (b-d) images of part of the cell within the red quadrant. AlexaFluor546-labelled C-peptide co-localizes, 
or is in close proximity, with early endosomes (see arrows). Showing is one representative z-section across one 
smooth muscle cell. 
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Figure 30. Immunohistochemistry of C-peptide internalisation and localization to early endosomes. HAEC 
were incubated for 3 h with 10 nmol/l C-peptide at 37°C. After fixation with paraformaldehyde, cells were 
incubated with rabbit anti-human antibody to C-peptide together with a mouse monoclonal antibody to the early 
endosome antigen 1 (EEA1) for 2 h and then with the appropriate secondary antibodies (see Methods). Cells were 
then washed and imaged by confocal microscopy. (a) Internalised C-peptide seen as green fluorescence vesicles. (b) 
Early endosomes, stained red. c Merging the two images shows colocalisation of most of the C-peptide with 
endosomes 
 
 
 
 
Figure 31. C-peptide co-localises with isolated early endosomes in UASMC. To identify early endosomes, we 
studied the internalization of Alexa Fluor 488-conjugated human transferrin, a specific marker of early endosomes, 
in the presence of Alexa Fluor 546-labelled Cpeptide in UASMC at 37°C, 5% CO2 for 10 min. Endosomes were 
isolated from other subcellular compartments by high-speed centrifugation and an aliquot of both the pellet (P) and 
of the endosomecontaining supernatant fraction (S) was used to quantitate the AlexaFluor 488–transferrin and Alexa 
Fluor 546–C-peptide fluorescence spectra by using a scanning spectrofluorimeter. The fluorescence of each 
molecule was expressed as a fraction of the total for each probe. AU, arbitrary units. *p>0.05, ***p<0.001 
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Figure 32. Internalized AlexaFluor488-labelled C-peptide traffics to lysosomes in UAMSC. UASMC were 
transduced with Organelle LightsTM Lysosomes-RFP, which induces expression of fluorescent Lamp1 protein, a 
specific lysosomal marker. UASMC were then incubated for 30 min with 1 mmol/l AlexaFluor488-labelled C-
peptide at 37ºC, washed with medium and imaged by using confocal microscopy. The yellow staining (c) 
corresponds to the merging of the green fluorescence (a; C-peptide) with the red fluorescence (b; Lysosomes) 
indicative of 82o-localization. The Figure shows images of a representative z-section across one vascular smooth 
muscle cell. 
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9.0  DISCUSSION 
T1D is a well-known risk factor for both micro- and macro-vascular disease with inflammation 
and endothelial dysfunction being major contributors to this risk. Findings indicate that a 
generalized inflammatory response is already present in the very early stages of diabetes74,75. 
Furthermore, T1D patients with microvascular complications exhibit increased production of 
inflammatory biomarkers, such as pro-inflammatory cytokines, over and above the levels 
detected in T1D patients without microvascular complications and healthy control subjects.68,71,77 
This risk is in part associated with the difficulty in maintaining euglycemic blood glucose 
conditions in the face of an appropriate exogenous insulin treatment.127 Administration of 
recombinant insulin does not contain C-peptide, a product of insulin biosynthesis, which exerts 
beneficial effects on some of the microvascular complications associated with diabetes.12-14  
In this study, we investigated the impact of human C-peptide specifically in the early 
process of atherogenesis in endothelial cells, vascular smooth muscle cells, and monocytes, three 
cellular target of vascular dysfunction. The few studies available on the topic, tested the effect of 
C-peptide on low and high glucose-induced proliferative activities of vascular smooth muscle 
cells, one major component involved in the formation of atherosclerotic plaque128,129. Here, we 
wanted to expand these studies by evaluating the potential effects of C-peptide in all cellular 
components of the vessel wall - endothelial cells, smooth muscle cells, and immune cell during 
hyperglycemia-induced vascular insult.  
The adhesion and migration of circulating monocytes into the subendothelial space is one 
of the key events in the early stages of atherogenesis130. This process is in part regulated by the 
expression of adhesion molecules, such as VCAM-1, on the surface of endothelial cells,131 and 
by the release of chemotactic factors, including IL-8 and MCP-1132. We found that C-peptide 
exerts an inhibitory effect on high glucose-induced up-regulation of the adhesion molecule 
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VCAM-1 on HAEC in vitro. C-peptide at the physiological concentration of 0.5 nmol/L reduced 
high glucose-induced expression of VCAM-1 to basal levels observed under normal glucose 
conditions. The decrease in VCAM-1 expression induced by C-peptide on HAEC was detected 
both at the mRNA and protein levels. This result is in line with another study demonstrating that 
C-peptide reduces expression of the adhesion molecule P-selectin and ICAM-1 on the rat 
microvascular endothelium during acute endothelial dysfunction in vivo17. In another model of 
vascular injury, C-peptide was shown to decrease polymorphonuclear leukocyte infiltration into 
the myocardium and therefore improving cardiac dysfunction18. Overall, these data point to an 
anti-inflammatory effect of C-peptide on the endothelium in condition of insult.This hypothesis 
is supported by recent in vivo data showing that survival of mice following endotoxic shock is 
improved after C-peptide administration8. In these mice, plasma levels of the pro-inflammatory 
cytokines tumor necrosis factor(TNF)-" and MCP-1 were also decreased, suggesting a decreased 
inflammatory response8. In the context of T1D patients, endothelial dysfunction with 
upregulation of VCAM-1 and inflammatory changes of the vessel wall are early events in the 
course of the disease71,133-135. These patients are insulin-dependent and take exogenous insulin to 
manage their blood glucose levels. It might well be that addition of physiological levels of C-
peptide to the traditional exogenous insulin therapy could be beneficial as a means to 
“counteract” the negative effect of high glucose on the endothelial cells of the diabetic patients.  
Another component of endothelial dysfunction that is affected by C-peptide is the 
secretion of the chemokines IL-8 and MCP-1 that facilitates endothelial cell interactions with 
circulating leukocytes. In support of other investigators91,136,137, we observed an increased 
secretion of both chemokines in the supernatant of endothelial cells exposed to 25 mmol/L 
glucose. Unique to this study, however, is the finding that C-peptide reduced high glucose-
stimulated IL-8 and MCP-1 secretion by endothelial cells to near or below the basal levels 
measured under normal glucose concentrations. In addition, adhesion of U-937 cells to 
endothelial cells stimulated with high glucose decreased after addition of C-peptide, an effect not 
detected when C-peptide was heat-inactivated. C-peptide at 0.5 nmol/L suppressed U-937 
monocyte attachment to HAEC exposed to 25 mmol/L glucose by 50% due to a C-peptide-
mediated inhibitory effect on VCAM-1, IL-8 and MCP-1 secretion by endothelial cells.  
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As predicted, another site of direct action of C-peptide are the U-937 cells. Previous 
studies from our laboratory75 and others137, have demonstrated that expression of several 
integrins, such as Mac-1 (CD11b), is increased on the surface of monocytes obtained from 
peripheral blood of T1D patients. Monocytes from these patients also show an increased 
adhesive capacity to endothelial cells in vitro75,137. In this current study, we demonstrated that C-
peptide reduces high glucose-stimulated secretion of IL-6, IL-8, MIP-1", and MIP-1# from LPS-
treated U-937 monocytes. Additionally, we observed that when C-peptide was added to 
30mmol/L glucose, there were a decreased number of adherent monocytes as compared to high 
glucose alone.  In low (5.6mmol/L) and intermediate (11 mmol/L) glucose conditions, C-peptide 
did not show any significant effects on the adherence of the treated U-937 monocyte to HAEC, 
thus suggesting that C-peptide exerts its most beneficial effects on the activated monocytes in 
conditions of insult from extreme hyperglycemia. 
During the development of the atherosclerotic plaque, proliferating VSMCs migrate from 
the media into early atherosclerotic lesions, secrete pro-inflammatory mediators, up-regulate cell 
adhesion molecules, and promote synthesis of matrix molecules required for the retention of 
lipoproteins138. In advanced human lesions, VSMCs and their secreted product constitutes up to 
70 to 80% of the content of the atherosclerotic plaques. Moreover, there is evidence suggesting 
that VSMCs may also be important for the stability of the atherosclerotic plaque through a 
formation of a firm fibrous cap139. Thus, the involvement of numerous VSMC functional 
abnormalities in diabetes, warrant the control of their proliferation to prevent diabetic 
complications. 
In this study, we showed that short-term exposure to C-peptide inhibited excessive 
proliferation of UASMC and AoSMC induced by high glucose in vitro110. Although this 
evidence in human VSMC is reported here for the first time, a suppressive effect of C-peptide on 
glucose-induced proliferation of VSMCs has been previously described by Kobayashi et al. in a 
rat aortic smooth muscle cell line128. Our and Kobayashi’s results support the view that 
physiological concentrations of C-peptide may exert a protective action on VSMCs in conditions 
of hyperglycemia by targeting the excessive VSMC proliferation. This effect might be specific to 
conditions of hyperglycemia, as it was not detected under normal glucose. In fact, VSMC 
cultured in normal glucose in the presence of C-peptide showed an increased proliferation, a 
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result also reported by Walcher et al.129. Based on these findings, it is tempting to speculate that 
C-peptide effects on proliferative activities of VSMCs in vitro is dependent on glucose 
concentrations in the culture medium, with stimulatory activity under normal glucose and 
inhibitory one in conditions of hyperglycemia. 
The mechanisms underlying the effects of C-peptide on the human vasculature are still 
largely unknown. Nevertheless, the signal transduction pathways that lead to the enhanced gene 
expression of adhesion molecules and inflammatory cytokine secretion in endothelial cells and 
monocytes require the translocation of the transcription factor NF-!B140. Therefore, this study 
investigated C-peptide effects on NF-!B activation in high glucose-stimulated model systems. In 
support of a previous study91, we confirmed that short-term high glucose exposure of endothelial 
cells stimulates NF-!B activation, however, our work moves the paradigm forward by 
demonstrating that exogenous addition of C-peptide significantly reduced high glucose-induced 
nuclear translocation of canonical components of NF-!B, p65 and p50. The suppressive effect on 
NF-!B activation and high glucose-induced VCAM-1 expression and IL-8 and MCP-1 secretion 
in HAEC was specific for C-peptide since heat-inactivated C-peptide was not able to elicit the 
same phenotype. Similarly, our work demonstrates that exogenous addition of C-peptide 
significantly reduced high glucose-induced nuclear translocation of NF-!B p65 and p50 subunits 
by reducing high glucose-induced phosphorylation of the cytoplasmic inhibitory protein $!%" in 
VSMCs. The involvement of NF-!B in VSMC proliferation in high glucose conditions is 
demonstrated by the fact that addition of PDTC and BAY 11-7082, two specific NF-!B 
inhibitors, abolished UASMC and AoSMC proliferation in vitro. The inhibitory effects of PDTC 
and BAY 11-7082 were also tested on cytokines secretion on high glucose-stimulated HAEC. 
In monocytes as well, C-peptide achieves its anti-inflammatory activity by leading to a 
reduction in NF-!B activation. Western blot and ELISA analyses of nuclear extracts from LPS-
treated U-937 cells exposed to high glucose showed a decreased nuclear translocation of NF-!B 
p50 and p65 subunits through a decreased phosphorylation of the cytoplasmic inhibitory protein 
I$B.  
Although the exact mechanism by which C-peptide affects phosphorylation of I$B is not 
known, one possible mechanism envisages that C-peptide turns off the cascade of 
  87 
phosphorylation events ultimately leading to the activation of kinase proteins involved in the 
phosphorylation of the inhibitor protein I!B. The phosphorylation cascade is carried through 
recruitment of several kinase proteins such as I!B, IKK" and IKK# and it is initiated at the level 
of the plasma membrane after the binding of a ligand to a membrane receptor (e.g. Toll-like 
receptor). At which level of the phosphorylation cascade C-peptide might act is unknown. 
Another NF-!B dependent upstream event that could likely be affected by C-peptide is 
represented by ROS generation. High glucose damages endothelial cells by increasing ROS136, 
141,142 and inducing apoptosis100,143. Moreover, ROS are powerful cellular activators of the 
nuclear-factor(NF)-!B pathway100,144-146. We therefore examined the effect of C-peptide on high 
glucose-induced ROS generation as the mechanism underlying its beneficial effects on 
endothelial cell dysfunction and apoptosis.  
We first assessed the level of apoptosis in condition of hyperglycaemia. We found that 
24-h exposure to high glucose increased expression levels and activity of cleaved (activated) 
caspase-3, which was reduced by addition of C-peptide to HAEC in vitro. Moreover, expression 
levels of the anti-apoptotic molecule Bcl-2 were up-regulated by C-peptide as compared to high 
glucose alone in HAEC. Although this evidence in HAEC is reported here for the first time, a 
protective effect of C-peptide against apoptosis has been described in different models. Using 
human neuroblastoma SH-SY5Y cells, Li ZG et al. found that C-peptide reduced high glucose-
induced apoptosis by promoting the expression of Bcl-2. 
As expected, C-peptide reduced ROS generation, a crucial upstream signaling event in 
the NF-!B pathway. The inhibitory effect of C-peptide on ROS generation in HAEC after 
overnight exposure to high glucose was observed immediately after the uptake of the dye and 
maintained overtime. By reducing ROS generation in HAEC, C-peptide reduces phosphorylation 
and degradation of the cytosolic NF-!B inhibitor I!B", leading to a reduced nuclear 
translocation of the NF-!B p50/p65 to the nucleus and reduced transcription of genes involved in 
inflammation and apoptosis. Moreover, we showed that C-peptide inhibits glucose-induced 
NAD(P)H oxidase activation, which is the major source of ROS in endothelial cells. This multi-
component enzyme includes a membrane-bound cytochrome b558, comprised of p22phox and 
gp91phox subunits, and the cytosolic adapter proteins p47phox and p67phox which are recruited to 
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the cytochrome during stimulation to form a catalytically active oxidase23.  Recruitment of 
p47phox and p67phox to the plasma membrane, requires presence of Rac-1, a member of the Rho 
family of small GTP-binding proteins, which complex with the cytosolic proteins to regulate 
NAD(P)H oxidase activity.  In this study, we found that glucose-induced Rac-1 protein levels at 
the plasma membrane of HAEC was inhibited by treatment with C-peptide for 30 min in vitro. 
Glucose-induced Rac-1 GTP-ase activity was also reduced by C-peptide in HAEC. All together, 
our findings demonstrate that C-peptide reduces ROS generation in glucose-exposed HAEC by 
inhibiting Rac-1-dependent NAD(P)H oxidase activation. 
Although there is a general consensus that C-peptide has physiological effects on several 
different cell types, the cell biology of C-peptide is for the most part unknown. In particular, it is 
not known how exactly C-peptides exerts intracellular activities in target cells. It was initially 
thought that C-peptide exerted its effect via nonchiral mechanisms rather than by binding to 
stereospecific receptors148; though specific binding to cultured rat pancreatic beta cells was 
demonstrated earlier149. More recently, specific binding of C-peptide to cellular membranes has 
been confirmed in several human cell types including human renal tubular cells, human 
fibroblast and saphenous vein endothelial cells106,150. Furthermore, C-peptide binding reaches full 
saturation at 0.9 nM; thus in healthy subjects, receptor saturation is achieved already at 
physiologic levels106. A specific C-peptide receptor has not been identified yet, although it is 
often suggested to be a G-protein-coupled receptor as deduced from effects of pertussis 
toxin106,151. 
C-peptide was shown to cross plasma membranes localizing in the cytoplasm of HEK-
293 cells and Swiss 3T3 fibroblasts151, where it was detected up to 1 h after uptake of the 
peptide. A nuclear localization of C-peptide in HEK-293 cells and Swiss 3T3 fibroblasts has also 
been demonstrated by the same group151. These findings demonstrate that once internalized in 
the cytoplasm, C-peptide is not rapidly degraded but remains intact, possibly interacting with 
sub-cellular components through which it might achieve its cellular effects. Recently, C-peptide 
was detected in the nucleoli where it promoted transcription of genes encoding for ribosomal 
RNA152.  
Given the lack of definitive knowledge on C-peptide cell biology, we investigated the 
process of internalization from the cell surface and sub-cellular localization of C-peptide in 
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target cells. In particular it was investigated whether C-peptide passively diffuses across the 
cellular membrane or whether it is actively translocated by a specific pathway of internalization, 
such as endocytosis. Our results showed that C-peptide binds to plasma membranes and 
internalizes in the cytoplasm of both cell types. The uptake of C-peptide was minimal after 5 min 
of incubation at 37ºC with AlexaFluor488-labeled C-peptide probe and began to be clearly 
visible after 10 min. As a control for specificity of the staining, cells were incubated with the 
AlexaFluor488 fluorescent dye alone and this incubation resulted in the absence of staining125. 
Further, when we tested whether C-peptide was directly translocated across the plasma 
membrane or whether it followed a vesicle-mediated pathway during internalization, we found 
that, the internalized C-peptide probe was evidently contained inside the endosome structures. C-
peptide eventually trafficked to lysosomes in live HAEC and UASMC.  
These findings indicate a process of C-peptide internalization from the cell surface within 
membrane-bound organelles of the endocytic pathway, and excluded direct translocation across 
the plasma membrane. Endosome localization of C-peptide would support the proposal that C-
peptide might achieve its cellular effects in part by signaling from these organelles. Endosomes 
interact with a complex network of tubules and vesicles distributed throughout the cytoplasm 
interconnected by a tightly controlled transport system153. In addition to their classical role as 
sorting stations for internalized activated receptor-peptides complexes on their way to lysosomal 
degradation, endosomes are emerging as crucial players in intracellular signaling154. Examples of 
signaling endosomes are the ones associated with epidermal growth factor receptors (EGFRs) 
whose downstream signaling factors such as SHC-adaptor protein (SHC), growth factor receptor 
bund protein 2 (GRB2) and mammalian Son-of-sevenless (mSOS) were found not only on the 
plasma membrane but on early endosomes as well155, suggesting that EGFR signaling continues 
in this compartment156. Another example of signaling endosomes is the one associated with 
nerve growth factor (NGF) that was found bound to its activated receptor TrkA and 
phospholipase C-)1 (PLC-)1) in endocytic organelles41. 
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10.0  CONCLUSIONS 
T1D patients lack physiological levels of insulin and C-peptide in their bloodstream due 
to the autoimmune destruction of their pancreatic beta cells. T1D patients are also at increased 
risk to develop both micro- and macro-vascular complications. Unfortunately, the standard of 
care for T1D patients is solely insulin-replacement therapy. Despite the recently published 
evidence of the beneficial effect of C-peptide replacement therapy on diabetes-associated 
vascular complications, C-peptide is not universally prescribed.  In this study, we have presented 
the most updated findings showing that: 
- C-peptide is internalized from the cell surface within early endosomes from which it affects 
intracellular signaling pathways;  
- In a model of high glucose-induced vascular dysfunction, C-peptide reduces endothelial 
dysfunction and apoptosis in human aortic endothelial cells; 
- C-peptide also reduces hyperglycaemia-induced proliferation in human vascular smooth muscle 
cells, a critical step in atherosclerosis; 
- C-peptide reduces inflammatory cytokines secretion from human monocytes and inhibits their 
adherance to the activated endothelium; 
- The molecular mechanism of C-peptide beneficial effects on the vasculature exposed to high 
glucose is through modulation of oxidative stress generation and downregulation of glucose-
induced NF-!B pathway. 
Although there is still much to learn about the cell biology and specific mechanism(s) of action 
of C-peptide, C-peptide is emerging as a new molecule with therapeutic potential in the 
treatment of several diseases with a strong inflammatory component, such as sepsis, T1D and 
diabetes-associated vascular complications.  
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